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ABSTRACT 
With the widespread resistance to current antimalarials and the great burden of malaria, the 
aim of this study was to determine the antimalarial activity of novel derivatives against the 
Plasmodium falciparum NF54 strain alone and in combination with quinine using the pLDH 
assay. The derivatives were designed such that they maintained the core chloroquinoline 
structure with known antimalarial activity with the addition of further scaffolds with a different 
mechanism of action in an attempt to produce compounds with good antimalarial activity with 
a lower probability of developing resistance.  
The twenty-seven 7-chloroquinolin-4-yl piperazine-1-yl acetamide (CQPA) derivatives and 
the nine 4-((7-chloroquinolin-4-yl) piperazine-1-yl) pyrrolidin-2-yl) methanone (CQPPM) 
derivatives all possessed antimalarial activity with 4 and 8 derivatives from each class 
respectively showed inhibitory activity below 10 µM. The most active derivative from each 
set of derivatives, CQPA-26 and CQPPM-9 displayed good antimalarial activity with IC50 
values of 1.29 µM and 1.42 µM, respectively compared to the standard antimalarial, quinine 
(IC50: 0.18 µM). The two most active derivatives displayed drug-like properties with 
favourable ionisation properties to confirm its ability to accumulate in the parasites’ digestive 
vacuole. In combination with quinine, these derivatives displayed synergistic and additive 
interactions, respectively. Morphological studies were carried out over a period of 48 hours 
to identify which parasite stage was most sensitive to the most active derivative from each 
class of derivatives. Both derivatives proved to show similar schizonticidal activity as the 
standard quinine with a lag in progression from the trophozoite stage. The inability to induce 
haemolysis indicated that the derivatives acted against the parasite and not the host red 
blood cell (<1% lysis), conferring a good safety profile. The low toxic nature of the 
derivatives was further demonstrated with the minimal toxicity towards human embryonic 
kidney epithelial cells and no effect on Artemia fransiscana brine shrimp viability (<5% 
lethality). Although the cyclopropyl and methyl substituted derivatives displayed good activity 
towards the intra-erythrocytic parasite, all the derivatives lacked larvicidal activity towards 
Anopheles arabiensis (mortality range: 0 - 5%). The derivatives showed no effect on the 
morphological structure of the Artemia fransiscana brine shrimp and the An. arabiensis 
larvae.  
This study highlights the good antimalarial activity of these derivatives coupled with a 
favourable safety profile as antimalarial agents and not larvicides.  The introduction of less 
bulky side chains proved to show a greater antimalarial activity against Plasmodium 
falciparum. 
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Chapter 1: Introduction 
1.1 Prevalence 
Malaria remains one of the main global health problems, causing 429 000 deaths 
annually, with 92% of deaths and 90% of cases occurring in Africa (WHO, 2016). 
According to the latest estimates by the World Health Organization (WHO), there were 
212 million malaria cases in 2016, with 13 countries accounting for 75% of malaria 
deaths (WHO, 2016) (Figure 1.1). Malaria transmission is generally stable in Western 
and Central Africa, unstable in Eastern Africa and unstable to absent in Southern Africa 
(Kibret et al., 2015). 
 
 
Figure 1.1: The distribution of malaria deaths (a) found in endemic countries (b)  
  (WHO, 2016). 
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In South Africa, malaria is currently endemic and restricted to the low altitude regions of 
three provinces, namely Limpopo, Mpumalanga, and KwaZulu-Natal (Maharaj et al., 
2012). Neighbouring countries such as Zimbabwe and Mozambique also have malaria-
endemic areas and contribute predominantly to imported cases of malaria in South Africa 
(Maharaj et al., 2013). Studies in 2010 indicate the highest death rate being reported in 
Limpopo (Figure 1.2). 
 
Figure 1.2: Number of malaria cases (bar graph) and deaths (line graph) by year and 
    endemic provinces in South Africa (Maharaj et al., 2013). 
 
1.2 Parasitology and entomology 
Malaria is caused by infection of red blood cells with the protozoan Plasmodium parasite, 
and transmitted by the bite of the female Anopheles mosquitoes, which depends on a 
blood meal to mature her eggs (WHO, 2013). There are five species of malaria parasites 
that infect humans, namely; P. falciparum, P. vivax, P. malariae, P. knowlesi and P. 
ovale (WHO, 2013). The predominant causative malaria parasite in South Africa is P. 
falciparum, transmitted primarily by Anopheles arabiensis mosquitoes. Malaria 
transmission occurs mostly between September and May, peaking in March (Maharaj et 
al., 2012). 
 
1.3 Life cycle of mosquito and malaria parasite 
The adult mosquito lays eggs that develop through several aquatic stages to adulthood 
(Figure 1.3). The eggs are laid on water surfaces and hatch into larvae within 2-3 days. 
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The larvae go through four growth stages and after 2-3 weeks eventually form pupae. 
The adult mosquito develops inside the pupae and emerges within 2-3 days. Larvae feed 
on bacteria and algae in the water, while the pupa does not feed during the development 
of the adult. The adult female transmits the malaria parasite to the human host by 
injecting sporozoites via her saliva during biting (Service, 1980). 
 
      Figure 1.3: The mosquito life cycle (Virtual Biology, 2014).  
 
Sporozoites found in a mosquito’s salivary gland are injected into the human host skin 
during a blood meal that the mosquito requires to develop her eggs (only female 
mosquitoes suck blood) (Figure 1.4). The sporozoites that reach a blood vessel travel to 
the liver and traverse several cells before developing in a hepatocyte in which the 
parasite numbers grow and develop into merozoites. Merozoites are released from the 
hepatocytes in vesicles and travel through the heart to the lungs, where the vesicles 
eventually disintegrate and release merozoites that can invade red blood cells to initiate 
the cyclic asexual stage of the malaria parasite. This cycle is repeated, causing fever 
each time the parasite erupts from the red blood cell. Symptoms can take 10-14 days to 
develop after the host has been bitten by an infective mosquito. Some of the infected red 
blood cells leave the asexual stage and instead of replicating, the merozoites develop 
into sexual forms called gametocytes which circulate in the blood stream. When this 
stage of the parasite is ingested by the mosquito during blood feeding, the male and 
female gametocytes mate in the mosquito’s midgut, penetrate the midgut wall to form 
oocysts in which the sporozoites develop. The oocyst then bursts and the sporozoites 
migrate to the salivary glands. At this stage, which takes about 10-14 days, the mosquito 
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becomes infective and will transfer the parasites to the next human host she feeds on. 
(Service, 1980; Klein, 2013). 
 
Figure 1.4: Malaria life cycle illustrating both sexual and asexual intra-erythrocytic and
    mosquito stages (Klein, 2013). 
 
1.4 Symptoms and diagnosis 
Symptoms may appear in cycles and occur at different intensities. The cyclic pattern of 
the malaria symptoms is due to the life cycle of malaria parasites as they develop and 
are essential indicators of a potential infection (WHO, 2013). Early detection and 
diagnosis of malaria is imperative to reduce malaria transmission. Delayed diagnosis and 
inappropriate treatment are associated with increased morbidity and mortality. The first 
symptoms of malaria may be mild and presents with fever, rigors, headaches and body 
pains (SA-DOH, 2016). A definitive diagnosis should be made by examining the parasite 
under a microscope via a Giemsa-stained blood smear (Blumberg, 2015).  
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1.5 Management 
Malaria cases can be prevented by vector control measures (preventing the mosquito 
from biting the human hosts), or by chemoprevention with the use of drugs that kill 
infections (WHO, 2016). 
1.5.1 Prevention by vector control 
Vector control plays a major role in decreasing malaria transmission in endemic areas. 
IRS and long-lasting insecticidal nets (LLIN’s) are the key methods in vector control 
(Brooke et al., 2013).  
1.5.2 Indoor residual spraying  
IRS involves spraying the interiors of homes using insecticides, such as dichloro-
diphenyl-trichloroethane (DDT), carbamates, or pyrethroids on average twice a year 
depending on the insecticide used and the duration of the transmission season. IRS 
reduces transmission by killing mosquitoes that enter the home. Thus, the outdoor 
resting components of the vector species populations are largely unaffected by IRS and 
are responsible largely for the low-level seasonal malaria transmission in South Africa 
(Brooke et al., 2013).  
1.5.3 Long-lasting insecticidal nets  
LLIN’s last longer than the conventional insecticidal nets. Together with insecticidal 
protection, they also serve as a physical barrier between the human and mosquito. 
Between 2000 and 2012, the numbers of households owning at least one bed net 
increased from 3% to 53% (WHO, 2014). However, between 2013 to 2014, the 
distribution of bed nets to sub Saharan Africa dropped (WHO, 2014). This opened a gap 
for resurgences in malaria transmission. 
 
1.6  Management protecting the human host:  
1.6.1 Treatment 
Prompt treatment with the appropriate drugs is vital in reducing malaria morbidity and 
mortality. The choice of antimalarial agents is dependent on the severity of the illness 
and the pattern of drug resistance of the parasite in the geographical area where 
malaria was acquired. In the late 1940s, quinine was used for both treatment and 
prophylaxis, while during the 1970s treatment changed to chloroquine. With the 
emergence of chloroquine resistance, treatment moved to sulphadoxine-pyrimethamine 
in 1988 and then to artemether-lumefantrine in 2001 (Blumberg et al., 2014). Artemisinin 
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is combined with other classes of drugs to form artemisinin combination therapy (ACT). 
The current first-line treatment for uncomplicated P. falciparum malaria is the artemisinin 
combination of artemether with lumefantrine (Figure 1.5). Second-line treatment of 
uncomplicated malaria is oral quinine, plus doxycycline or clindamycin. Parenteral 
artesunate is the preferred treatment of severe malaria with quinine (intravevenous) 
used when artesunate is unavailable, followed by oral treatment once the patient can 
tolerate it. Mixed infections of Plasmodium are treated with ACT followed by primaquine 
(Figure 1.5) (Blumberg, 2015; SA-DOH, 2016). 
In high risk provinces, the recommended first-line treatment for uncomplicated malaria is 
accessible at any level of public healthcare. Parenteral forms of antimalarials are only 
accessible at hospital levels. Uncomplicated malaria in South Africa is treated at an 
outpatient level, except for high-risk population groups which are treated on admission 
to hospital (Ukpe et al., 2013).  
 
Figure 1.5: Algorithm for treatment of malaria in South Africa (SA-DOH, 2016). 
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1.6.2 Prophylaxis 
The determination of necessitating chemoprophylaxis depends on the area travelling to, 
the risk the traveller has of being exposed to the mosquito and contracting malaria. The 
greater the risk, the greater the need for chemoprophylaxis. There are currently three 
regimens used for chemoprophylaxis in South Africa as recommended by the South 
African Department of Health (SA-DOH): 
- Mefloquine that is taken weekly starting one week before entering the area, weekly 
while in the area, and four weeks after returning. 
- Doxycycline that is taken daily starting one day before entering the area, daily while 
in the area and four weeks after returning. 
- Atovaquone-proguanil that is taken daily one or two days before entering the area, 
daily while in the area and for 7 days on returning (SA-DOH, 2016). 
The reason that mefloquine and doxycycline are to be continued for a month after 
returning from malaria risk area is that they only act on parasites within red blood cells, 
whereas atovaquone-proguanil acts on parasites within hepatocytes as well as their 
erythrocytic stage (Figure 1.6) (Schwartz, 2012). 
 
Figure 1.6: Malaria prophylaxis agents by site of action (Schwartz, 2012). 
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1.7 Development of resistance 
The biggest threat to treatment and vector control is the emergence of resistance, by the 
parasites to current drug treatments, and mosquitoes to the insecticides used in vector 
control programmes. 
1.7.1 Resistance by the malaria parasite to current treatment 
According to the WHO, parasite resistance exists to antimalarial drugs in three of the 
malaria species, namely: P. falciparum, P. vivax and P. malariae. This results in 
incomplete clearance of the parasite following treatment with an antimalarial (WHO, 
2014). Drug resistance leads to treatment failures and increases the burden of the 
infection. Resistance is usually initiated through a spontaneous mutation that gives rise 
to a reduced level of sensitivity of the parasite to the antimalarial. Resistance can 
become firmly established within a parasite species and can last for long periods of time 
(WHO, 2015). In all endemic provinces in South Africa, markers associated with 
sulphadoxine-pyrimethamine and chloroquine resistance were prevalent by 2003 
(Hargreaves et al., 2003, Maharaj et al., 2012). 
Western Cambodia was the first to report artemisinin resistance, with failure rates of 
artemisinin combination therapies rising (Ashley et al., 2014). Reports of resistance to 
artemisinin has spread to Southeast Asia. Artemisinin resistance is characterised by 
slow clearance of the parasite. On the Thailand Myanmar border, the mean half-life for 
parasite clearance increased from 2.6 hours in 2001 to 3.7 hours in 2010 (Ashley et al., 
2014). 
The artemisinin resistance is linked to marked point mutations in a region called the K-
13 propeller region which alter the protein synthesis pathways in the parasites 
development (Straimer et al., 2015). The emergence of artemisinin resistance, has 
raised great concern for the future efficacy of antimalarial treatment and an increased 
risk for the spread to the African continent (Ashley et al., 2014). 
1.7.2 Resistance by the malaria mosquito to vector control methods 
The increased use of insecticides in malaria vector control programmes has led to 
resistant genes in many vector populations and continues to be of concern as the 
number of resistance reports continue to increase. Recent reports of insecticide 
resistance in South Africa indicated that Anopheles. arabiensis was resistant to DDT, 
but sensitive to pyrethroids. However, An. funestus was found to be resistant to 
pyrethroids, but sensitive to DDT and carbamates (Hargreaves et al., 2003; Maharaj et 
al., 2012). According to the WHO, 60 of the 78 reporting countries, reported resistance 
to at least one insecticide and 49 countries reported resistance to insecticides in two or 
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more insecticide classes (WHO, 2015). In 2014, pyrethroid resistance was the most 
commonly reported insecticide class (WHO, 2015). The 2015 data of a study conducted 
on An. arabiensis affirmed the presence of pyrethroid and DDT resistance in KwaZulu-
Natal (Brooke et al., 2015) (Table 1.1). 
Table 1.1: Mean percentage mortalities of samples of An. arabiensis following exposure
   to listed insecticides by class (Brooke et al., 2015). 
Vector control strategies using IRS and LLIN’s, play a vital role in reducing malaria 
transmission and case number in South Africa. The increase in distribution and intensity 
of resistance to insecticides compromises the effectiveness and gains of vector control 
methods. The insecticidal resistance could lead to increases in malaria incidence and 
mortality (Brooke et al., 2015). 
 
1.8 Classification of antimalarials 
Early detection and treatment of uncomplicated malaria is essential to prevent the 
development of severe malaria to reduce the time frame in which a person carries the 
parasite in the blood reducing the risk of further transmission and subsequently death 
(WHO, 2016). 
1.8.1 4-Aminochloroquinolines 
Quinine, first extracted from the cinchona bark in the 1600’s, is one of the oldest 
antimalarials. Once its therapeutic potential was realised, research into synthetic 
analogues based on the quinine template (Figure 1.7) began, resulting in compounds 
such as the 4-aminochloroquinoline, chloroquine (Figure 1.7) (O’Neill et al., 2012). 
Insecticide 
(concentration) 
Insecticide class Sample 
size 
Mean % 
mortality 
Resistance (R) 
or susceptibility 
(S) 
Deltamethrin 
(0.05%) 
Pyrethroid 191 87.21 R 
DDT (4%) Organochloride 140 83.85 R 
Bendiocarb (0.1%) Carbamate 145 94.1 R 
Pirimiphos-methyl 
(0.25%) 
Organophosphate 45 100 S 
Fenitrothion (1%) Organophosphate 44 100 S 
Control (untreated) - 234 2.74 - 
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Figure 1.7: Structure of quinine and chloroquine (O’Neill et al., 2012). 
Chloroquine was first synthesised in 1934 and became the most widely used 
antimalarial by the 1940’s (O’Neill et al., 2012).  Chloroquine is effective against the 
erythrocytic form of chloroquine sensitive strains of the Plasmodium parasite in which 
chloroquine is able to accumulate at high concentrations within the parasite vacuole. 
The success of this class as antimalarials has been based on its antimalarial efficacy, 
low toxicity and cost-effectiveness (O’Neill et al., 2012). 
Chloroquine, lumefantrine, mefloquine and quinine antimalarial inhibitory effects are due 
to their ability to cleave ferric haem which eventually leads to death of the parasite. 
Parasites grow by degrading haemoglobin after invading red blood cells in the acidic 
part of the parasite’s vacuole (Egan, 2008). The resultant free ferric haem or  
ferriprotoporphyrin IX (FPIX) is toxic to the parasite, which polymerises it to non-toxic 
haemozoin for survival (Figure 1.8). The 4-aminochloroquinolines like chloroquine 
exhibit their antimalarial action by inhibiting the formation of the haemozoin, leading to 
the accumulation of free toxic FPIX. Free toxic FPIX leads to a cascade of events that 
result in death of the parasite (Egan, 2008). The aminoquinoline drugs prevent the 
formation of the haemozoin crystal by binding to the FPIX or forming a drug-FPIX 
complex (Pisciotta & Sullivan, 2008). The toxicities involve morphological changes in the 
parasite, haemoglobin accumulation, FPIX accumulation, membrane function 
impairment, destruction of glutathione, inhibition of proteolytic enzymes and the release 
of calcium from acidic stores (Fitch, 2003). 
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Figure 1.8: Proposed representation of haemozoin formation in Plasmodium falciparum. 
Red blood cell (RBC) cytoplasm ingested into parasite (Pf) via a cytosome (C) and transported to 
the digestive vacuole (DV) by transport vesicles (TV). Once delivered, haemoglobin (Hb) is 
digested to short peptides (c) that are exported to the DV and degraded to amino acids (d). The 
haemoglobin releases ferriprotoporphyrin IX which undergo various processes (e,f,g) and are 
eventually delivered to the lipid body (LB) where assembly of the haemozoin crystal take place 
(i,j,k) (Egan, 2008). 
1.8.2 Artemisinin 
Artemisinin(1) combination therapy is the standardised first-line treatment for P. 
falciparum malaria in endemic areas and has markedly reduced global morbidity and 
mortality rates due to malaria (WHO, 2016). The artemisinin compounds include 
artemisinin, artemether, arteether and artesunate. The active metabolite, 
dihydroartemisinin (2) acts rapidly by inhibiting major metabolic processes in the parasite 
and killing them. Artemisinin exhibits antimalarial activity against multiple stages of 
parasite development (Muangphrom, 2016). Artemisinin is a sesquiterpene lactone with 
an endoperoxide bridge (1) that requires activation to generate the active free radical 
species (2). The proposed mechanism of action of the artemisinins involves cleavage of 
the peroxide bridge by free or haem-bound iron to produce reactive free radicals. The 
free radicals alkylate and oxidise proteins resulting in rapidly killing of the parasite 
(Krungkrai, 2016). Artemisinins have positively impacted on malarial treatment with their 
high efficacy and fast action. 
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Figure 1.9: Artemisinin (1) dihydroartemisinin (2), doxycycline (3), lumefantrine (4) 
    (Krishna et al., 2004). 
 
1.8.3 Arylamino alcohol derivatives  
Lumefantrine, quinine and mefloquine are among the drugs classed as arylamino 
alcohols. Lumefantrine (4) is used in combination with artemether and interacts in a 
synergistic manner (Schlitzer, 2007). The mechanism of action of arylamino alcohols 
involve interference with haem digestion. The arylamino alcohol derivatives accumulate 
in the parasite food vacuole and inhibit haem digestion (quinine) and form toxic 
complexes with free haem (mefloquine and lumefantrine) (Schlitzer, 2007). 
1.8.4 Antifolate drugs 
These classes of antifolate antimalarials interfere with folate metabolism, a process 
essential to malaria parasite survival (Nzila, 2006) (Figure 1.10). This is a valuable 
target as it is specific for the parasite and not the host. 
Class 1: Dihydrofolate reductase (DHFR) is an enzyme that catalyses NADPH 
(nicotinamide adenine dinucleotide phosphate)-dependant reduction of dihydrofolate to 
tetrahydrofolate in the malaria parasite. Compounds that inhibit DHFR include proguanil 
and pyrimethamine. These drugs act as tissue shizonticides and are slow-acting blood 
schizonticides. Proguanil is used in with atovaquone for treatment of P. falciparum 
infection (Blumberg, 2015). 
Class 2: Sulphonamides such as sulfadoxine act as inhibitors of the enzyme 
dihydropteroate synthase (DHPS) in the folate pathway in the parasite. They act as 
analogues of para-aminobenzoic acid and competitively inhibits DHPS in the pathway 
from forming dihydropteroate (Schlitzer, 2007). The combination of sulfadoxine with 
pyrimethamine (DHFR inhibitor) has synergistic effects increasing its effectiveness 
against P. falciparum (Schlitzer, 2007). Unfortunately, this synergy and the effectiveness 
of antifolates have declined due to widespread resistance worldwide. Resistance to the 
DHFR and DHPS inhibitors is conferred by single mutations of the gene encoding for 
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the respective enzyme, resulting in substitutions in the amino acid chain (Saifi et al., 
2013). 
 
Figure 1.10: Antifolate drug effects on folate metabolism in P. falciparum  
                 (adapted from Chango et al., 2011). 
 
1.8.5 Antibiotics 
Antibiotics are used in combination with rapid acting drugs as they are slow acting, with a 
late onset of antimalarial activity during the second replication cycle of the parasite. The 
antibiotics have a characteristic delayed death effect by only killing the parasite once it 
has invaded the new host cell. Antibiotics such as doxycycline and clindamycin exert 
antimalarial activity through their action on the parasites apicoplast. The antibiotic blocks 
the expression of the apicoplast genome resulting in a loss of functional apicoplasts in 
developing merozoites (Dahl, 2006). 
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Figure 1.11: The delayed death effect of antibiotics on the malaria parasite results from
      slow growth inhibition (Pradel et al., 2010). 
 
 During the first replication cycle (RC1), in which antibiotics are administered, merozoites 
(M) are formed and infect new erythrocytes. The parasites develop to trophozoites (T). 
During the second replication cycle (RC2) the parasites are arrested in the schizont (S) 
stage with no formation of new merozoites. The third replication cycle (RC3) is therefore 
inhibited (Figure 1.11). Doxycycline (Figure 1.9 (3)) is the most widely used antibiotic to 
treat malaria in combination with quinine, as well as prophylactically where mefloquine or 
atovaquone-proguanil is contra-indicated. Clindamycin is considered safe in pregnancy 
and young children, in contrast to doxycycline which is contraindicated in these patients 
(Schlitzer, 2007; Blumberg, 2015).  
 
1.9 Need for novel antimalarial agents 
With the current line of therapy being faced with lack of efficacy due to resistant strains 
of the parasites, development of novel derivatives in treating malaria is vital. Current 
antimalarial drugs mostly target the asexual blood stage of the parasite’s life cycle.  
Moving towards elimination of malaria, parts of the parasites life cycle beyond the blood 
stages and possibly a dual target (against erythrocytic and vector stages) needs to be 
investigated. 
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Current antimalarials mainly act by inhibiting haemozoin formation necessary for 
survival of the parasite, while others interfere with folate metabolism. Current drugs that 
target these mechanisms such as chloroquine and proguanil respectively have shown 
great efficacy and relative safety. However, with the development of resistance to these 
drugs, alternative ways to inhibit these sites or multiple sites with redesigned derivatives 
need to be studied.  
The current antimalarial trend, involves combination therapy of two or more agents into 
a single tablet (artemether-lumefantrine) to improve compliance and efficacy (WHO, 
2015). However, extensive spread of resistance to classical antimalarials necessitates 
the search for promising antimalarials with novel chemical structures and mechanism of 
action (Muregi et al., 2010). The recent widespread interest in hybrid molecules over 
combination molecules has been backed by encouraging efficacy and toxicity reports 
(Muregi et al., 2010). Hybrid drugs involve linking two molecules with individual activity 
into a single agent. This provides a dual functionality effect (Inam et al., 2015). Hybrid 
drugs show advantageous characteristics over combination therapy in terms of cost 
constraints and have a lower risk of drug-drug adverse interactions. However, the 
disadvantage is that it poses difficulties in adjusting the ratio of activity at the different 
targets (Muregi et al., 2010). In recent deliberate rational drug design of antimalarials, 
hybrid molecules have been designed with multiple targets (Figure 1.12).  
Figure 1.12: Rationale of hybrid drug design (Klhan et al., 2017). 
 
One example involves the development of a trioxaquine hybrid molecule containing a 
trioxane linked to a quinolone. The trioxaquine hybrid boasts the advantage of dual 
activity of the quinoline and trioxane fragments; with the quinoline showing antimalarial 
activity similar to that of potent antimalarials such as chloroquine and the trioxane 
moiety displaying similar alkylating activity to the artemisinins. The trioxaquine hybrid 
offered more effective antimalarial activity than the individual components in 
combination (Muregi et al., 2010). This would imply that the interaction of the 
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pharmacophores of two molecules in a single hybrid is superior to the individual 
molecules in combination. This is useful in designing drugs such as the 
aminoquinolines, where the resistance is due to inability to access the target rather than 
alteration of the target. This study employs the principle of ‘covalent bitherapy’ by 
developing hybrid molecules that restore the activity of other drug classes that have 
become ineffective due to resistance. 
The first set of compounds in the current study, 7-chloroquinolin-4-yl piperazine-1-yl-
acetamide derivatives is comprised of a 4-aminochloroquinoline group linked via a 
piperazine group to a substituted acetamide (Figure 1.13). The rationale behind the 
design and synthesis of these compounds was that the 4-aminochloroquinoline will 
promote haem binding, the piperazine will act as a linker and the acetamide group will 
exhibit DHFR inhibitory effects (Rastelli et al., 2003; Madapa et al., 2009). 
The second set of hybrid compounds evaluated in this study is the 4-(7-chloroquinolin-4-
yl) piperazin-1-yl)pyrrolidin-2-yl)methanone derivatives (Figure 1.14); where it was 
proposed that the sulphonamide group would inhibit DHPS, the piperazine will act as a 
linker and the 4-aminoquinoline group would inhibit haem binding. 
 
 
Figure 1.13: Hybrid antimalarial with 4-aminochloroquinoline group (A) linked to an 
       acetamide (C) group via a piperazine linker (B) (personal communication,
       Azam, 2014). 
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Figure 1.14: Basic structure of 4-(7-chloroquinolin-4-yl) piperazin-1-yl) pyrrolidin-2- 
       yl)methanone derivatives, bearing a 4-aminoquinoline (A), piperazine (B)
       and pyrrolidine ring (C) with a sulphonamide group (D) (personal 
       communication, Azam, 2014). 
The components of these hybrids compounds were selected based on specific features 
of the individual compounds: 
• Both sets of derivatives contain an aromatic nucleus similar to chloroquine which 
is known to have high binding affinity for haem in the malaria parasite (Leed et 
al., 2002). The specificity of chloroquine in accumulating and binding to a unique 
target within the malaria parasite illustrates its’ importance in including similar 
structural features in to novel hybrid compounds. 
•  Clindamycin, an antibiotic that contains a pyrrolidine ring has shown positive 
antimalarial results against P. falciparum and is used in combination with either 
quinine or chloroquine (Lell et al., 2002).  
• The sulphonamide group on the second group of derivatives is proposed to show 
similar activity to sulphonamides in inhibiting the enzyme DHPS in the folate 
sythesis pathway. A sulphonamide, sulphadoxine is used in combination with 
pyrimethamine in treating malaria in pregnancy and young children (Rogerson et 
al., 2000).  
• The acetamide group on the first set of derivatives in this study, is characteristic 
of proguanil, an antimalarial that inhibits the enzyme DHFR in the folate 
synthesis pathway (Hogh et al., 2000).  
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In recent studies, piperazine and pyrrolidine derivatives showed antimalarial activity 
against P. falciparum (Mendoza et al., 2011). Studies by Ekoue-Kovi et al., (2009), 
showed that introducing a sulphonamide side chain to chloroquine analogues showed 
high antimalarial activity and low resistance index. These studies provide a platform for 
the rational design of dual functionality hybrid molecules with two or more 
pharmacophores in the development of promising novel antimalarials. This strategy, 
was undertaken in this study to create novel antimalarial hybrids which are able to 
restore the efficacy of traditional pharmacophores and surmount the rapid development 
of resistance. 
Despite the availability of current antimalarials, and the use of vector prevention 
methods, mortality rates in endemic areas are still high (WHO, 2016). The emergence of 
resistance to current antimalarials, as well as to insecticides places the importance on 
developing new antimalarials to overcome the current resistance. Despite the resistance 
to the aminoquinoline core structure, this pharmacophore displays unique antimalarial 
ability and low host cell toxicity, which warrants its’ inclusion into new hybrid drugs. The 
design and synthesis of the new drugs in this study are centred around the basic 
pharmacophore of the aminoquinoline, with the addition of side chains to decrease 
resistance as well as increase the overall antimalarial activity of the hybrid derivatives. 
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1.10 Aims & Objectives 
The aim of this study was to investigate the in vitro antimalarial activity against P. falciparum 
and larvicidal activity against An. arabiensis of 7-chloroquinolin-4-yl piperazine-1-yl 
acetamide derivatives and 4-((7-chloroquinolin-4-yl) piperazine-1-yl) pyrrolidin-2-yl) 
methanone derivatives. 
In order to achieve this, the main objectives of this study were as follows: 
➢ To determine the antimalarial activity of a total of 36 novel derivatives using the 
parasite lactate dehydrogenase (pLDH) assay. 
➢ To evaluate the effect of lead derivatives in combination with standard antimalarials 
to assess drug interactions. 
➢ To determine the larvicidal effects of the derivatives on Anopheles arabiensis 
mosquitoes to assess a possible dual action of the derivatives. 
➢ To assess the toxicity of the derivatives against the host red blood cell using the red 
blood cell haemolysis assay. 
➢ To determine the selectivity index of the derivatives for P. falciparum parasites 
compared to human epithelial cells. 
➢ To determine the stage-specific morphological effects of the most active compounds 
to elucidate antimalarial mechanisms of action. 
➢ To evaluate the drug-like properties of the most active derivatives using Lipinski’s 
predictions. 
➢ To evaluate toxicity of the derivatives toward Artemia fransiscana (brine shrimp) 
using a lethality assay. 
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Chapter 2: Methodology 
2.1 Compounds and derivatives 
All compounds were purchased from reputable commercial suppliers at the best quality. The 
derivatives were synthesised, characterized and the structures confirmed by spectroscopic 
techniques by Prof A. Azam from the Department of Chemistry at Jamia Islamia Millia, New 
Delhi (India). The purity of the compounds were established on the basis of CHNS elemental 
analysis in which values lie in the range ±0.3. Two sets of compounds were synthesised, 
twenty seven 7-chloroquinolin-4-yl piperazine-1-yl acetamide derivatives (Table 2.2) and 
nine 4-((7-chloroquinolin-4-yl) piperazine-1-yl) pyrrolidin-2-yl) methanone derivatives (Table 
2.1). The derivatives were prepared in dimethyl sulfoxide (DMSO) to a   10 mM stock and 
stored in 1 ml aliquots at -70˚C until needed for experiments. 
2.2 Culturing of asexual stages of parasite 
Culturing and maintenance of the chloroquine-sensitive strain of P. falciparum (NF54) 
malaria parasites was carried out in accordance with the methods described by Trager and 
Jansen (1977), Freese et al. (1988) and departmental protocols (Appendix A). The P. 
falciparum (NF54) strain was used as it is the most pathogenic form of malaria found in 
humans exclusively (Klein, 2013). Furthermore, the intention of further gametocyte studies 
with the P. falciparum strain provided the basis in using the NF54 strain. Aseptic techniques 
were used in a laminar flow unit with 70% ethanol to wipe down containers and surfaces. 
2.2.1 Preparation of reagents 
The phosphate buffered saline (PBS) was prepared by dissolving 4 mM potassium 
chloride (Sigma Aldrich®), 2 mM potassium phosphate monobasic (Fluka®), 4 mM sodium 
chloride, 0.004 M sodium phosphate dibasic dehydrate (Sigma Aldrich®) in autoclaved 
MilliQ® water and then the pH adjusted to 7.4 with 10 mM NaOH (Sigma Aldrich®). The PBS 
solution was autoclaved and stored at 4˚C. 
The incomplete culture medium was prepared in autoclaved MilliQ® water with 10.4 g/L 
Roswell Park Memorial Institute (RPMI) medium 1640 (Gibco®), 30 mM 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) buffer (Boehringer Mannheim®), 
0.02 M anhydrous glucose (Merck®), 0.3 mM hypoxanthine (Sigma Aldrich®) and 0.1 mM 
gentamicin (Sigma Aldrich®). The preparation was stirred for one hour and filter sterilised 
through a 0.22 µm filter (Sterivex™). The incomplete experimental media was prepared as 
the incomplete culture medium with the omission of gentamicin and stored at 4˚C. 
Lipid-rich bovine serum albumin (AlbuMAX®) (Gibco®) was prepared (Appendix B) in 
incomplete experimental medium as a 5% (w/v) solution and stirred vigorously for at least 2 
21 
 
hours at 37˚C. The solution was filter sterilised using a 0.22 µm filter (Sterivex™) and stored 
at -20˚C. 
Complete culture medium was prepared in incomplete culture medium with 10% (v/v) 
AlbuMAX® (Section 2.2.1) and 4.2 ml 5% (w/v) sodium bicarbonate (Sigma Aldrich®) under 
sterilised conditions. 
Table 2.1: The core structure and side chains of the 4-((7-chloroquinolin-4-yl) piperazine-1-
        yl) pyrrolidin-2-yl) methanone derivatives. 
 
Compound 
designation 
R-group Compound 
designation 
R-group 
 
CQPPM-1 
  
CQPPM-6 
                            
 
CQPPM-2 
  
CQPPM-7 
 
 
CQPPM-3 
  
CQPPM-8 
             
 
CQPPM-4 
  
CQPPM-9 
 
 
CQPPM-5 
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Table 2.2: The core structure and side chains of the 7-chloroquinolin-4-yl piperazine-1-yl 
       acetamide derivatives. 
Compound designation with R Group substituent 
 
CQPA-1 
 
CQPA-2 
 
CQPA-3  CQPA-4 
 
 
 
CQPA-5 
 
 
 
 
 
 
 
CQPA-6 
 
 
 
 
 
 
 
CQPA-7 
 
 
CQPA-8 
 
 
CQPA-9 CQPA-10 
 
 
CQPA-11 
 
 
 
 
 
CQPA-12 
 
 
 
 
CQPA-13 CQPA-14 
 
 
 
 
 
CQPA-15 CQPA-16 
 
CQPA-17 
 
 
 
 
 
 
CQPA-18 
 
 
 
 
 
 
CQPA-19 CQPA-20 
CQPA-21 
 
CQPA-22 
 
CQPA-23 
 
 
 
 
 
 
CQPA-24 
CQPA-25 
 
 
CQPA-26 
 
CQPA-27 
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2.2.2 Collection and preparation of uninfected red blood cells 
Human ethics was obtained from the University of the Witwatersrand Human Research 
Ethics committee (clearance certificate number: M140669, Appendix C) to draw blood from 
healthy volunteers. Whole, fresh blood was collected in Vacuette® blood vial tubes 
containing an anticoagulant (acid citrate dextrose) from healthy volunteers who were not on 
antimicrobials, anticoagulants or antimalarials. The blood was washed by centrifugation at 
671 g for 5 min to remove the white blood cells, plasma and platelets. The supernatant was 
discarded and RBCs washed three times with PBS (pH 7.3) after which incomplete 
experimental media (Section 2.2.1) was added to maintain a 50% haematocrit and stored at 
4˚C for a maximum of 10 days before discarding.  
2.2.3 Maintenance of P. falciparum NF54 strain culture 
Bioethics clearance was obtained from the University of Witwatersrand Human Research 
Ethics committee to culture malaria P. falciparum parasites (clearance certificate number:07-
11-2017, Appendix D). P. falciparum (NF54 strain) was cultured in a tissue culture flask 
(Sigma Aldrich®) at a 5% haematocrit and 5% parasitaemia. On a daily basis, slides of the 
cultures were prepared (Section 2.2.4) and examined microscopically. Based on the 
microscopic findings (Figure 2.1), blood was added when the parasitaemia was >5% 
trophozoites/schizonts and synchronised when in the ring stage (Section 2.2.5). The spent 
media from the culture was replaced with complete culture medium (Section 2.2.1) before 
the culture was gassed for 30 seconds with 3% oxygen, 4% carbon dioxide and 93% 
nitrogen before being incubated at 37˚C in a static position.  
2.2.4 Giemsa staining 
Giemsa-stained thin blood smears were prepared from settled cultures on a daily basis to 
assess parasitaemia, morphology and stage (Figure 2.1). The Rapi-diff stain set (Clinical 
Sciences Diagnostics) was used to stain the parasite in the red blood cell. The slide was 
immersed into solution 1 (thiazine dye) once to fix the slide, and immersed into solution 2 
(eosin) five times to stain the RBCs, then rinsed in water and dried and immersed in solution 
3 (methylene blue) ten times to stain the parasites. The slides were microscopically 
(Olympus®) examined under oil immersion at 1000X magnification. The stage, morphology 
and percent parasitaemia (Equation 2.1) was determined after viewing and counting ten 
fields of the stained thin blood smear. 
 
Equation 2.1: Calculation to determine percentage parasitaemia of a culture from a thin 
  blood smear. 
% Parasitaemia =
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑎𝑠𝑖𝑡𝑖𝑧𝑒𝑑 𝑅𝐵𝐶𝑠
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑢𝑛𝑖𝑛𝑓𝑒𝑐𝑡𝑒𝑑 𝑅𝐵𝐶𝑠+𝑝𝑎𝑟𝑎𝑠𝑖𝑡𝑖𝑠𝑒𝑑 𝑅𝐵𝐶𝑠
x 100 
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Figure 2.1: The intra-erythrocytic cycle of P. falciparum with inset photographs at 1000x  
        magnification showing the appearance of the parasites at different stages upon
        Giemsa staining. 
 
2.2.5 Synchronisation of parasites 
The cultures were synchronised when predominantly in the ring stage (Figure 2.1) with a 5% 
(w/v) D-sorbitol (Lambros et al., 1979) to allow the D-sorbitol to lyse the trophozoites and 
schizonts and keep the culture in synchrony. This is based on the differential permeability of 
the red blood cell membranes where uninfected red blood cells and early ring staged 
infected red blood cells are less permeable than later staged Plasmodium-infected red blood 
cells (Lambros et al., 1979). This property is used to selectively kill the mature stages of the 
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parasite by osmotic shock while the uninfected red blood cells and ring stages remain 
unaffected. The pellet was treated with 20 ml of 5% (w/v) D-sorbitol (Sigma Aldrich®) 
following a 20 minute incubation at 37˚C. Thereafter the suspension was centrifuged at 400 
g for 5 minutes and supernatant discarded. The culture was washed thrice in PBS before 
adding the complete culture media and being gassed (Section 2.2.3) and returned to the 
flask to be re-incubated. 
 
2.3 Antimalarial activity 
2.3.1 Parasite lactate dehydrogenase assay 
The in vitro anti-Plasmodium activity in this study was determined using a modified method 
of the parasite lactate dehydrogenase (pLDH) assay as described by Makler et al. (1993). 
Lactate dehydrogenase (LDH) is an essential metabolic enzyme, which catalyses the 
dehydrogenation of lactate and produces pyruvate with nicotinamide adenine dinucleotide 
(NAD) as a co-enzyme. The assay distinguishes parasite LDH from host LDH by using 3-
acetylpyridine adenine dinucleotide (APAD) as an analogue of NAD (Makler et al., 1993). 
The pLDH converts APAD to APADH, which in turn reduces yellow nitro blue tetrazolium 
(NBT) to purple formazan salts. The percentage of parasite survival was determined 
measuring the conversion of NBT. Malstat™ was used to disrupt the red blood cell 
membranes, exposing the parasite to NBT for the enzymatic reaction to occur. 
The 1.96 mM NBT (Sigma-Aldrich®) and 0.24 mM phenazine ethosulphate (PES) (Sigma-
Aldrich®) solutions were freshly prepared for each experiment in MilliQ® water, hand filtered 
(0.22 µm) and stored at 4˚C in the dark. The Malstat™ reagent was prepared by combining 
Triton™ X-100 (1 ml/L), 0.5 mM APAD (Sigma-Aldrich®), calcium-L-lactate (0.18 mM) 
(Sigma-Aldrich®) and trisaminomethane (TRIS) buffer (27.5 mM Tris base (Prolabo®) in 
MilliQ®  water and stirred at 37˚C until dissolved. The freshly prepared solution was filtered 
(0.22 µm) and stored in the dark. 
2.3.2 Experimental set-up 
Parasite cultures were synchronised in the ring stage with 5% (w/v) D-sorbitol (Section 
2.2.5). Parasitised red blood cells were prepared at a 2% parasitaemia and 2% haematocrit 
in complete experimental culture media (Section 2.2.1). One hundred microliters of the 
parasitised red blood cells was plated out in all wells of a 96 well microtitre plate except the 
blank wells (Figure 2.2). A 2% haematocrit of non-parasitised red blood cells was prepared 
and plated out in 3 wells (100 µl) of the last row to serve as an uninfected red blood cell 
control, with the remainder of the last row serving as the untreated parasitised red blood cell 
control (Figure 2.2). The plates were incubated in sterile candle jars containing MilliQ® water 
26 
 
to ensure a humidified environment was maintained at 37˚C for 24 hours. The approximate 
micro-anaerobic conditions (3% CO2, 17% O2, 80% N2) were achieved by burning candles in 
the candle jar (Trager and Jensen, 1977). 
 After 24 hours, compounds and controls prepared in incomplete culture medium, were 
plated out (12.5 µl) and 12.5 µl of incomplete culture medium added to the untreated 
uninfected and parasitised red blood cell wells. The plates were returned to the candle jar 
and re-incubated for 48 hours at 37˚C after re-lighting the candles in the candle jar at 24 
hour intervals. 
After incubation, plates were sealed using parafilm and frozen at -70˚C for 1 hour, after 
which they were thawed for 2 hours in the incubator at 37˚C in the dark. The contents of the 
plates were re-suspended on a Thermo™ plate shaker for 2 minutes at 1200 rpm. 
Maintaining the same plate layout, 25 µl of the re-suspended red blood cell lysate was 
transferred to a separate sterile 96 well plate. One hundred microliters of Malstat™ and 20 µl 
of NBT/PES (1:1) solution were added to each well, plates sealed and shaken on a 
Thermo™ plate shaker for 30 seconds before being incubated for 40 minutes at 37˚C in a 
sealed plastic container to develop. A 5% (v/v) acetic acid (50 µl) was added to each well to 
stop the reaction and air bubbles were removed with a hairdryer to prevent inaccurate 
absorbance readings. The absorbance of the formazan products was read at 620 nm. 
 
Figure 2.2: Plate layout in the pLDH assay indicating decreasing drug dilutions (from top to
        bottom) in triplicate (horizontally) with colour changes indicating parasite 
        presence (dark purple) and no parasite (clear to light purple). 
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2.3.3 Data analysis 
For compounds showing >50% inhibition of parasite growth, serial dilutions were prepared to 
determine the concentration that inhibited 50% of parasite growth (IC50 value) and log 
sigmoidal dose response curves generated using GraphPad® Prism Version 5.02. For 
compounds inhibiting less than 50% parasite growth, the percent parasite growth inhibition 
was reported. Each experiment was repeated thrice to produce mean ± standard deviation. 
2.3.4 Combination studies 
With multi-drug resistance being reported in most parts of the world, new antimalarial 
regimens advocating combination therapy are in place (WHO, 2015). The concept of 
combination therapy is based on the potential synergistic effects of using two or more 
combined drugs to increase efficacy and delay the development of resistance (Berenbaum, 
1989). The pLDH assay was used (Section 2.3.1) with an additional two fold dilution factor 
taken into account to account for the addition of two compounds. Two of the three most 
active derivatives were combined with quinine. Based on the IC50 value of the individual 
derivatives, the test compound and quinine were combined in different ratios which were 
prepared such that as the concentration of the one increased, the concentration of the other 
decreased (Table 2.3). Serial dilutions were prepared from each set of ratios, from which log 
sigmoid dose response curves were constructed to determine IC50 values for the drug alone 
and the combinations. To assess the interaction between the test compound and quinine, an 
isobologram was constructed (GraphPad® Prism Version 5.02) and generated using the 
Fractional Inhibitory concentration (FIC) equation (Equation 2.2). 
 
 
Equation 2.2: Calculation to determine the FIC using the IC50 values of the compound alone
  and in combination. 
 
Table 2.3: Concentration ratios at which derivatives were combined with quinine (B-H) and
       positive controls containing single compounds alone (A & I). 
Concentration 
(µM) 
A B C D E F G H I 
Quinine  50 50 35 20 7.5 0.2 0.02 0.002 0 
Derivative  0 0.05 0.5 0.75 1.5 25 35 50 75 
 
𝐹𝐼𝐶 =
IC
50 of compound in combination 
IC
50 
of compound alone 
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The values on the isobologram above the line were interpreted as being antagonistic, below 
as synergistic, and those near the line as additive (Figure 2.3). To verify the interaction 
interpreted from the isobologram, the sum of the FIC values (∑FIC) for the derivative with 
quinine at each combination ratio was calculated and interpreted as follows: <0.5 as 
synergistic, 0.5-2.0 as additive, while that > 2 as antagonistic (Berenbaum, 1989; van Zyl et 
al., 2010). 
 
Figure 2.3: Visualisation of possible pharmacological interactions between two compounds
         in combination using an isobologram (adapted from Berenbaum et al., 1989). 
 
2.4 Stage determination 
This study was carried out to determine the specific effects of the two most active derivatives 
on the asexual stage in the life cycle of the malaria parasite (Moseley, 2012). The IC50 and 
IC90 values of the most active derivative from each class of compounds was determined from 
the log sigmoid dose-response curves (Section 2.3.3). Working solutions of the derivatives at 
the IC50 and IC90 values were prepared in incomplete experimental culture media to 
determine concentration effects on the parasite. The study was carried out in 25 cm3 tissue 
culture flasks (Sigma Aldrich®) to enable easy removal of blood samples. Parasites were 
synchronised in the ring stage (Section 2.2.5) and prepared at a 2% parasitaemia and 2% 
haematocrit in complete culture media. The synchronised parasites (5.4 ml) were placed in 
each flask to which the derivatives (600 µl) were added. A negative control was prepared 
with a 2% haematocrit and 2% parasitaemia in the absence of any drug. The standard 
antimalarial agent, quinine was also prepared at its IC50 and IC90 values for comparison. The 
29 
 
cultures were gassed in an atmosphere of 3% oxygen, 4% carbon dioxide and 93% nitrogen 
for 15 seconds, sealed and placed in the incubator at 37˚C in a static position. Every 8 hours 
the flasks were removed from the incubator and agitated gently to re-suspend the contents 
to remove samples (20 µl) to make thin blood smears (Section 2.2.4) from the centrifuged 
sample (671 g for 5 minutes). After each time interval of preparing a blood smear, the 
cultures were re-gassed and returned to the incubator. The blood smears were analysed 
microscopically at 1000x magnification (Olympus®) to determine total parasitaemia, percent 
parasitaemia at each stage and to note morphological changes in the parasite. 
2.5 Measurement of drug-likeness 
Keeping in line with the Medicines for Malaria Venture requirements that the oral 
bioavailability of new drugs must be determined, as such the solubility and permeability 
properties of the derivatives were predicted using the Lipinski’s rule of five (Ro5) predictions 
to determine the bioavailability of the derivatives. The drug-likeness of the most active 
derivatives to be able to permeate into the acidic digestive vacuole of the P. falciparum 
parasite (Figure 1.8), was measured using the physicochemical properties of the derivatives 
in comparison to the reference drug quinine (Figure 2.4). Drug-likeness refers to the drug-
like permeability properties for the purpose of this investigation (Bhal et al., 2007). The 
Lipinski’s Ro5, also known as the Pfizer’s rule of five is a rule to evaluate drug-likeness or 
determine if a chemical compound with a certain pharmacological or biological activity has 
properties that would make it a likely   drug that would be orally bioactive in humans (Lipinski 
et al., 1996). In this study, the partition coefficient was used as a predictor of the lipid 
solubility of the derivatives. The Lipinski’s ‘rule of five’ concept was applied as outlined by 
Lipinski et al. (1996), such that drugs with a molecular weight less than 500, a partition 
coefficient (Log P) less than 5, possessing less than 5 H-bonds and less than 10-H bond 
acceptors were considered to have drug-like properties. Two dimensional structures of the 
derivatives were constructed using ACD/ChemSketch software (freeware version). 
Thereafter, solubility and permeability predictions were performed using ACD/iLab version 2. 
Derivatives that violated more than one of the rule of five parameters were considered as 
non-drug-like, having poor pharmacokinetic properties.  
The ionisation constants (pKa values) as predicted by the ACD/iLab version 2 software, 
were used to determine the degree of ionisation of the derivatives at physiological pH 7.4 
(red blood cell cytosol) and pH 5 (parasite digestive food vacuole), was derived using the 
Henderson-Hasselbalch equation (equation 2.3) (Po et al., 2001). 
 
Equation 2.3: Henderson-Hasselbalch equation to determine the percentage ionisation for
   weak acids and weak bases. 
% 𝐼𝑜𝑛𝑖𝑠𝑎𝑡𝑖𝑜𝑛 =  100
1 + antilog (pKa - pH) 
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Figure 2.4: Workflow of methodology in applying the Lipinski rule of five (adapted from Bhal 
         et al., 2007). 
 
2.6 Larvicidal assay 
All the derivatives were screened against Anopheles arabiensis mosquito larvae to 
determine its activity, according to the WHO protocols with slight modifications (WHO, 2005).  
2.6.1 Determining concentration for screening compounds 
In order to determine the most appropriate concentration at which to screen compounds 
against the larvae, the lethal concentration at which 50% of the larvae are killed (LC50) with 
dichlorodiphenyltrichloroethane (DDT) (Supelco®) (positive control) was obtained and the 
concentration determined from that value. A stock solution of DDT in ethanol was prepared 
at a concentration of 1 mg/ml (2817.7 µM) with 1:10 dilutions in ethanol prepared. The 
experiment was carried out five times as explained below (Section 2.4.2), and the LC50 value 
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determined using Probit analysis with IBM SPSS® Statistics version 22 software. The 
concentration of screening the derivatives was set at 10 times higher than the LC50 of DDT. 
For purposes of generating a graph, GraphPad® Prism version 5.02 was used and verified to 
produce the same LC50 as probit analysis (IBM SPSS® Statistics version 22). 
2.6.2 Bioassay 
Animal ethics was obtained from the University of Witwatersrand Animal Research Ethics  
Committee (clearance certificate: 07-11-2017-O, Appendix D). Mosquito larvae were 
obtained from a DDT-susceptible strain of Anopheles arabiensis (KGB) housed in the Botha 
de Meillon Insectary at the National Institute for Communicable Diseases, Johannesburg and 
fed standard larval food twice a day. Batches of 25 third to fourth instar larvae (male or 
female) of An. arabiensis (KGB) were gently introduced into disposable plastic cups (173.2 
cm2) containing a total of 25 ml of distilled water. To each test cup, 250 µl (0.5 µM) test 
derivative or positive control DDT (0.5 µM) or untreated background control with water or 
untreated solvent controls of DMSO or ethanol was added and incubated for 24 hours at 25-
28˚C. The larvae in each cup were fed standard larval food by tapping enough powder to 
cover the water surface. After 24 hour incubation, dead larvae were gently prodded and non-
responsive larvae recorded as dead. Percentage mortality was calculated according to 
Equation 2.4. 
 
 
Equation 2.4: The equation used to calculate the percent mortality of larvae caused by the
              compound tested. 
 
2.6.3 Data analysis 
Each derivative was tested once in each experiment and the experiment carried out 5 times 
to produce a mean ± standard deviation. Compounds showing significant larivicidal effects 
were further tested to produce the concentration of derivative required to kill 50% of the An. 
arabiensis larvae (LC50) and generate a log dose-probit regression line using the IBM SPSS® 
Statistics version 22 program. For compounds showing mortality <10%, the percentage 
mortality was reported. 
 
 
 
% Mortality = 
(% survival in untreated control)−(% survival in treated control)
% survival in untreated control
 x 100 
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2.7 Toxicity assays 
Toxicity assays are paramount in the screening of novel compounds. The essence is not 
merely determining the safety of a compound, but also to characterise the possible toxic 
effects it can produce. 
2.7.1 Haemolysis assay 
The haemolysis assay was carried out to determine the toxicity profile of the compounds, by 
determining whether the test derivatives could induce lysis of the red blood cell membrane 
by evaluating haemoglobin release. The haemolytic assay was carried out using aseptic 
technique on healthy freshly obtained red blood cells (Section 2.2.2) as described by Hayat 
et al. (2011).  
2.7.1.1 Preparation of test derivatives and classical antimalarials 
Stock solutions (10 mM) of test derivatives and positive controls chloroquine (Sigma-
Aldrich®) and quinine (Sigma-Aldrich®) were diluted to a screening concentration of 50 µM in 
incomplete experimental medium (Section 2.2.1) with the appropriate dilution factor taken 
into account. 
2.7.1.2 Preparation of plates 
In a sterile 96 well-plate, 25 µl of each of the 50 µM derivatives were plated out in triplicate 
with 200 µl of a 2% haematocrit red blood cell suspension (Section 2.2.2) and 25 µl of 
incomplete experimental media. The last row of the plate was used for the controls, with 50 
µl of 2.9% (v/v) Triton™ X-100 solution (Sigma-Aldrich®) in PBS (pH 7.4) plated out in 3 
wells as the positive, 100% lysis positive control and 50 µl incomplete culture media as a 0% 
lysis negative control in the remaining wells. 
The plates were incubated in a humidified candle jar at 37˚C for 48 hours. Thereafter, the 
plates were gently agitated and centrifuged at 377 g for 5 min. The supernatant (50 µl) from 
each well was transferred to a second non-sterile 96 well-plate, with 150 µl water added to 
each well. The absorbance was read at 412 nm and the percentage haemolysis calculated 
according to equation 2.5. 
% 𝐻𝑎𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 =  
Absorbance (test compound)−Absorbance (0% haemolysis control)
Absorbance (100% haemolysis control)−Absorbance( 0% haemolysis control)
𝑋 100   
Equation 2.5: Determination of the percent haemolysis caused by the parasite on the red
   blood cells. 
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2.7.1.3 Data analysis 
All experiments were carried out in triplicate to produce a mean ± standard deviation. 
Compounds that produced <40% haemolysis were reported as a percentage haemolysis at 
50 µM. For compounds displaying >40% haemolysis, an IC50 was determined. 
2.7.2 Cell viability assay 
The cell viability assay measures the ability of cells to reduce the tetrazolium dye, 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), to its insoluble formazan 
product, resulting in a purple colour. Since this requires a functioning mitochondria, the 
assay effectively measures the metabolic activity of live cells (Mosmann, 1983). 
2.7.2.1 Preparation of medium and reagents for cell culturing 
Incomplete medium consisted of 13.53 g/l Dulbecco’s Modified Eagles Medium (DMEM) 
(Sigma Aldrich®) and 44 mM NaHCO3 (Sigma Aldrich®) double distilled MilliQ® water and 
stirred until dissolved. The solution was filter sterilised through a 0.22 µm filter and stored at 
4˚C.  
To prepare complete culture medium to maintain the cells, the incomplete medium was 
supplemented with 10% foetal bovine serum and stored at 4˚C. 
The MTT salt solution was prepared as a 12 mM solution in PBS (pH 7.3) and filter sterilised 
through a 0.22 µm filter and stored at 4˚C. 
2.7.2.2 Cell maintenance 
Human embryonic kidney epithelial (HEK-293) cells were maintained at 37˚C in a humidified 
5% CO2 environment (clearance certificate: W-CJ-161129-2, Appendix E). Cells were viewed 
microscopically at 40x magnification (Olympus® CKX41) to determine if the cells appeared 
healthy and confluent (Figure 2.4). Spent media was discarded and cells rinsed once with 10 
ml sterile PBS (pH 7.3). Fresh complete culture medium (20 ml) was then added to the cells 
together with 200 µl penicillin 100 IU/ml-1 and streptomycin 100 IU/ml-1 solution. The culture 
was then returned to the incubator or trypsinised to split the confluent cells (Section 2.5.2.3) 
or to be used in experiments (Section 2.5.2.4). 
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Figure 2.5: Morphological appearance of HEK-293 cells. 
2.7.2.3 Splitting cells 
The cells were split when they were confluent, as viewed microscopically (Figure 2.5). The 
media was discarded and cells rinsed once with PBS (10 ml) as above. Thereafter, 3 ml 10% 
trypsin was added. The flask was incubated at 37˚C for 1 minute and agitated to lift cells. 
Complete culture media (3 ml) was added to inactivate the trypsin and the cell suspension 
transferred to a 50 ml sterile tube, and re-suspended in complete culture medium up to 10 
ml. This was used in the cell viability assay (Section 2.5.2.4). One millilitre of the suspension 
was used to re-establish the culture in fresh complete culture media to which 200 µl 
penicillin/streptomycin was added and incubated for a further 48 hours before this process 
needed to be performed again. 
2.7.2.4 MTT cell viability assay 
The cell suspension as prepared above (Section 2.5.2.2), was adjusted to 10 000 cells per 
well for all viability experiments. The cell density of this latter cell suspension was 
determined by staining the cells with 0.2% (w/v) tryphan blue (Sigma Aldrich®) and 
microscopically counting the cell number on a haemocytometer at 100x magnification to 
determine the average cell count per ml. The cell suspension was adjusted in complete 
experimental culture medium such that 1x104 cells/180 µl were plated per well, except to   
the background control wells which contained no cells only 180 µl complete culture medium. 
The remainder of the row served as the untreated controls with 100% cell growth. The plate 
was incubated for 24 hours at 37˚C in a humidified environment with 5% CO2. After 
incubation, the derivatives or controls (20 µl) were plated out in triplicate with camptothecin 
(Molekula®) as the positive control and 20 µl DMEM added to background and untreated 
control wells. The plates were once again incubated under the same conditions for 48 hours. 
Thereafter, wells were treated with 40 µl MTT (12 mM) for 2 hours and the plates were 
centrifuged at 671 g for 5 minutes before the supernatant (180 µl) was discarded and 
replaced with 180 µl DMSO to solubilise the formazan crystals. The plates were agitated 
slightly on a Thermo plate shaker for 2 minutes at 1000 rpm and left to stand for a further 10  
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minutes in the dark, to ensure complete dissolution of the crystals. The test absorbance was 
read at 540 nm (purple formazan colour), with a reference wavelength of 690 nm (unreacted 
yellow MTT) using a UV-Vis plate spectrophotometer (Labsystems Multiskan LC). The 
percent cell growth was calculated using Equation 2.6. 
Equation 2.6: Determination of percentage cell viability (growth) taking the reference and
   test wavelengths into account. 
2.7.2.5 Data analysis 
Serial dilutions were prepared for compounds that inhibited >60% cell growth, to determine 
the IC50 values and generate log sigmoidal dose response curves using GraphPad® Prism 
Version 5.02. For compounds that inhibited <60% cell growth, the percentage inhibition at 50 
µM was reported. All experiments were repeated at least in triplicate to produce a mean ± 
standard deviation. 
 
2.7.3 Safety Index 
The safety index was calculated as the selective activity of the compounds against the P. 
falciparum parasites in comparison to their cytotoxicity on the nomalised cell line. The safety 
index was calculated as a cytotoxicity to antiplasmodial activity ratio as in Equation 2.7 
(Manohar et al., 2010). 
𝑆𝑎𝑓𝑒𝑡𝑦 𝐼𝑛𝑑𝑒𝑥 (𝑆𝐼) =
𝑐𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 (IC
50
) 
𝐴𝑛𝑡𝑖𝑚𝑎𝑙𝑎𝑟𝑖𝑎𝑙 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (IC
50
)
 
Equation 2.7: The safety index of the derivatives in targeting P. falciparum in preference to
   human cell lines. 
 
2.7.4 Lipid peroxidation assay 
Reactive oxygen species are thought to be involved in the pathogenesis of malaria and in 
the progression of the disease (D’Souza et al., 2006). The lipid peroxidation assay as 
outlined by Gulcin (2007) was used to assess if the compounds induced death to the 
parasites via this pathway as a potential mechanism of action. 
 
 
%Cell viability = 
Absorbance drug (540 nm)−Absorbance drug (690 nm)
mean absorbance untreated control(540 nm)−mean absorbance untreated control(690 nm)
x100 
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2.7.4.1 Preparation of reagents 
Sodium phosphate buffer (0.2 M): A 100 ml solution of NaH2PO4.H2O (2.76 g) (Sigma-
Aldrich®) and 200 ml solution of NaH2PO4.2H2O (7.12 g) (Sigma-Aldrich®) were prepared 
individually in MilliQ® water and 78 ml and 122 ml of each solution respectively was 
combined. The pH was adjusted to 7 and the solution stored in a glass container at 4˚C. 
Ammonium thiocyanate (3.94 M): Ammonium thiocyanate (30 g) (Merck®) was dissolved in 
100 ml MilliQ® water in a fume hood and stored at 4˚C away from light. 
Ferrous chloride (20 mM): Ferrous chloride (0.127 g) (Fluka®) was freshly prepared on the 
day of experiment where it was dissolved in 50 ml 3.5% (v/v) HCl and further diluted to a 5 
mM working solution. 
Linoleic acid emulsion: The emulsion was freshly prepared on the day of the experiment. 
Linoleic acid (51.2 µl) (Fluka®) and Tween-20 (51.2 µl) (Sigma-Aldrich®) were mixed and the 
volume made up to 10 ml with sodium phosphate buffer (pH 7) (Section 2.8.1). 
2.7.4.2 Lipid peroxidation experimental assay 
Twenty five microliters of each derivative (50 µM) was plated out to triplicate wells except for 
the last row with DMSO (25 µl) as the untreated control. The derivatives and control were 
reacted with the linoleic acid emulsion (125 µl) and sodium phosphate buffer (100 µl) in a 
non-sterile 96 well plate. The plates were shaken for 1 minute at 1000 rpm and incubated at 
37˚C for 24 hours. Thereafter, 25 µl of the reaction was reacted with 70% ethanol (150 µl), 
ammonium thiocyanate (40 µl) and ferrous chloride (40 µl) and compared to the positive 
control, Trolox™ (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). The absorbance 
was read at 492 nm and the inhibition of lipid peroxidation was calculated as per Equation 
2.8. 
% 𝐿𝑖𝑝𝑖𝑑 𝑝𝑒𝑟𝑜𝑥𝑖𝑑𝑎𝑡𝑖𝑜𝑛 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙) −  𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑡𝑒𝑠𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑/𝑠𝑡𝑑) 
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
x100 
Equation 2.8: Determination of the percent lipid peroxidation inhibited by the test   
  compound, where std: standard control. 
 
2.7.4.3 Data analysis 
All experiments were carried out in triplicate to produce a mean ± standard deviation. 
Compounds which caused <40% lipid peroxidation inhibition were reported as a percent 
peroxidation inhibition. 
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2.7.5 Brine shrimp lethality assay 
The brine shrimp lethality assay was carried out to determine the toxicity of the derivatives 
on a whole organism in comparison to human cell lines. The method was adapted from the 
lethality assay as reported by Ruebhart et al. (2009).  
2.7.5.1 Hatching eggs 
To hatch the Artemia franciscana eggs, 0.5 g of the cysts were incubated at 25˚C for 24 
hours in 500ml salt water (32 g/l) (Aquarium Systems®), under a continuous source of 
artificial light (60 Watts), while being aerated vigorously by a rotary pump (Figure 2.6). After 
24 hours, the newly hatched shrimp (nauplii) were placed in a sorting tray with 200 ml salt 
water and held for 15 minutes under the artificial light source to concentrate the nauplii to a 
suitable density as they are attracted to light. Thereafter the nauplii were plated out for use in 
the bioassay. 
 
Figure 2.6: The design of the brine shrimp hatchery setup.  
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2.7.5.2 Bioassay 
 Animal ethics was obtained by the University of Witwatersrand Animal Research Ethics 
Committee (clearance certificate: 07-11-2017-O, Appendix F) for the use of Artemia brine 
shrimp. An average of 20-40 nauplii were plated out (50 µl) in each well of a sterile 48 well 
plate. Salt water (32 g/L) (197.5 µl) was added to each well, followed by 2.5 µl of derivative 
(0.5 µM) in triplicate to be screened. All drugs were prepared in DMSO ensuring it equates 
to <1%. Potassium dichromate (0.5 µM) (125 µl) was plated out as the positive control and a 
drug-free control containing salt water was used as a negative control. Once plated out, the 
nauplii were viewed under a microscope (8x magnification; Zeiss©) to record any dead 
nauplii before incubation (dead at T0). The plates were incubated for 24 hours at 25˚C. After 
24 hours the number of dead nauplii in each well was microscopically counted under 8x 
magnification (dead at T24). Thereafter, in order to determine the total number of nauplii in 
each well, 100 µl of acetic acid (5%, v/v) was added to all wells to kill the nauplii. The total 
number of nauplii was then counted (total nauplii) and used to calculate the percentage 
mortality using equation 2.9. 
% Mortality = 
Dead nauplii @ T24 −Dead nauplii @ T0
Total nauplii
 x 100 
Equation 2.9: Determination of the percent mortality of nauplii caused by the derivatives and 
  controls after a 24 hour period. 
 
2.7.5.3 Data analysis 
Each experiment was repeated in triplicate to produce a mean ± standard deviation. 
Compounds showing significant mortality of brine shrimp were analysed as in Section 2.7.1 
using the IBM Statistics®22 probit analysis. For compounds not showing any significant 
mortality, the nauplii treated with each compound were further investigated microscopically 
(Olympus® CKX41) for any significant morphological changes along with those showing 
significant mortality. 
 
2.8 Statistical analysis 
All experiments were carried out in at least triplicate to produce a mean ± standard deviation 
(s.d.) and each experiment independently repeated three times. To determine if there was a 
statistically significant difference between a test compound and control, an unpaired 
students T-test was performed using GraphPad® Prism Version 5.02 software, with a p-value 
of less than 0.05 considered to be significant.  
39 
 
CHAPTER 3: Results 
3.1 Antimalarial Activity 
All twenty-seven 7-chloroquinolin-4-yl piperazine-1-yl acetamide derivatives and the nine 4-
((7-chloroquinolin-4-yl) piperazine-1-yl) pyrrolidin-2-yl) methanone derivatives inhibited more 
than 40% malaria growth on initial screening at 50 µM (range: 52.04 - 97.23% inhibition). 
The derivatives were further assessed and displayed antimalarial activity with an IC50 range 
of between 1.29 – 53.98 µM (Table 3 .1) and 1.42 – 19.62 µM (Table 3.2). Derivative CQPA-
26 showed the most promising antimalarial activity from the 7-chloroquinolin-4-yl piperazine-
1-yl acetamide derivatives against the P. falciparum parasite (IC50 :1.29 ± 3.35 µM) (Figure 
3.1) followed by CQPA-25 with an IC50 value of 1.72 µM compared to quinine (IC50: 0.18 ± 
0.05 µM). Derivative CQPPM-9 showed the most promising activity from the 4-((7-
chloroquinolin-4-yl) piperazine-1-yl) pyrrolidin-2-yl) methanone derivatives against the P. 
falciparum parasite with an IC50  value of 1.42 µM compared to quinine (p < 0.05). Derivative 
CQPA-6 (53.98 ± 3.01 µM) and CQPPM-2 (19.62 ± 3.21 µM) were the least active in 
inhibiting malaria growth. 
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Figure 3.1: Log sigmoid dose-response curve indicating the antimalarial activity of the most
         active compound from the 7-chloroquinolin-4-yl piperazine-1-yl acetamide 
         (CQPA-26) and 4-((7-chloroquinolin-4-yl) piperazine-1-yl) pyrrolidin-2-yl)  
         methanone (CQPPM-9) derivatives in comparison to the standard antimalarial
         agent, quinine. 
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Table 3.1: Results showing antimalarial activity and cytotoxicity profile of the 7-  
       chloroquinolin-4-yl piperazine-1-yl acetamide derivatives. 
  
Antimalarial 
activity
IC50  (µM) ± sd % cell inhibition at 
50 µM 
% rbc lysis at 50 µM 
CQPA-1 34.19 ± 1.07 34.91 ± 0.21 0.95 ± 0.37
CQPA-2 42.16 ± 3.42 44.08 ± 4.89 1.32 ± 0.59
CQPA-3 21.85 ± 3.66 32.65 ± 5.06 1.43 ± 0.39
CQPA-4 35.35 ± 7.33 40.5 ± 8.44 1.42 ± 0.41
CQPA-5 30.13 ± 7.40 51.68 ± 8.48 0.1 ± 0.01
CQPA-6 53.98 ± 3.01 43.05 ± 3.72 0.1 ± 0.01
CQPA-7 18.75 ± 3.32 46.49 ± 3.61 0.1 ± 0.01
CQPA-8 29.88 ± 5.73 43.47 ± 3.73 0.08 ± 0.04
CQPA-9 23.76 ± 3.00 33.62 ± 3.52 0.2 ± 0.11
CQPA-10 18.99 ± 3.04 53.85 ± 0.88 0.25 ± 0.18
CQPA-11 24.48 ± 5.78 43.23 ± 5.78 1.18 ± 0.55
CQPA-12 31.57 ± 2.91 43.86 ± 1.08 0.3 ± 0.17
CQPA-13 19.07 ± 1.42 43.43 ± 2.44 0.37 ± 0.29
CQPA-14 17.08 ± 2.31 51.38 ± 4.62 0.68 ± 0.41
D
er
iv
at
iv
e Chemical Structure R-Group Cytotoxicity Profile
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Antimalarial activity
IC50 (µM) ± sd % cell inhibition at 
50 µM
% rbc lysis at 50 µM
CQPA-15 11.06 ± 1.97 59.94 ± 6.01 0.42 ± 0.28
CQPA-16 35.92 ± 3.11 19.45 ± 9.55 0.67 ± 0.31
CQPA-17 24.16 ± 5.73 55.25 ± 2.94 0.79 ± 0.38
CQPA-18 13.10 ± 2.89 38.25 ± 4.84 0.51 ± 0.24
CQPA-19 1.85 ± 0.52 50.2 ± 5.25 0.28 ± 0.16
CQPA-20 18.95 ± 7.53 22.47 ± 3.79 0.09 ± 0.02
CQPA-21 9.70 ± 1.51 51.93 ± 4.89 0.15 ± 0.09
CQPA-22 51.41 ± 4.96 48.93 ± 10.30 0.21 ± 0.1
CQPA-23 10.81 ± 1.60 44.32 ± 2.89 0.14 ± 0.07
CQPA-24 13.11 ± 2.59 39.88 ± 0.72 0.49 ± 0.16
CQPA-25 1.72 ± 0.17 34.93 ± 2.81 0.59 ± 0.46
CQPA-26 1.29 ± 3.35 54.88 ± 0.48 0.4 ± 0.28
CQPA-27 21.79 ± 2.06 42.05 ± 5.44 0.09 ± 0.02
Quinine 0.18 ± 0.05 23.46 ± 3.78 0.1 ± 0.01
Camptothecin n/a 78.11 ± 6.6 n/a
Cytotoxicity Profile
D
er
iv
at
iv
e Chemical Structure R-Group
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Table 3.2: Results showing antimalarial activity and cytotoxicity profile of the 4-((7- 
       chloroquinolin-4-yl) piperazine-1-yl) pyrrolidin-2-yl) methanone derivatives. 
 
  
Antimalarial 
activity
IC50 (µM) ± sd MTT IC50 (µM) ± sd % rbc lysis at 50 
µM ± sd
CQPPM-1 3.45 ± 0.83 24.35 ± 5.75 1.74 ± 0.64 7.06
CQPPM-2 19.62 ± 3.21 14.67 ± 2.09 0.85 ± 0.50 0.75
CQPPM-3 4.08 ± 0.99 57.66 ± 11.86 0.42 ± 0.25 14.15
CQPPM-4 3.21 ± 0.72 53.10 ± 6.32 0.81 ± 0.63 16.54
CQPPM-5 6.33 ± 0.89 46.02 ± 5.77 0.09 ± 0.02 7.27
CQPPM-6 4.02 ± 0.63 57.67 ± 8.38 0.10 ± 0.01 14.33
CQPPM-7 4.21 ± 0.75 37.96 ± 4.12 0.13 ± 0.05 9.02
CQPPM-8 5.33 ± 1.20 64.06 ± 3.10 0.18 ± 0.13 12.03
CQPPM-9 1.42 ± 0.32 81.24 ± 8.73 0.09 ± 0.02 57.14
Quinine 0.18 ± 0.05 275.6 ± 16.46 0.10 ± 0.01 1494.58
Camptothecin n.t 0.11 ± 0.01 n.t n.t
 n.t: not tested
Cytotoxicity Profile
Selectivity 
index
Derivative
Chemical Structure R-
group
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3.2 Combination studies 
The most active derivative from the 7-chloroquinolin-4-yl piperazine-1-yl acetamide group 
demonstrated a synergistic interaction when combined with quinine and the most active 
derivative from the 4-((7-chloroquinolin-4-yl) piperazine-1-yl) pyrrolidin-2-yl) methanone 
group demonstrated an overall additive interaction in combination with quinine. The ∑FIC 
values for CQPA-26 and CQPPM-9 were 0.29 ± 0.0014 and 1.31 ± 0.03, respectively (Figure 
3.2). 
 
 
Figure 3.2: Isobolograms showing the drug interactions between the most active CQPA-26
        (A) and CQPPM-9 (B) derivatives with quinine. 
 
3.3 Stage determination 
The total parasitaemia of the most active derivative from the 7-chloroquinolin-4-yl piperazine-
1-yl acetamide derivatives, CQPA-26 and the most active derivative from the 4-((7-
chloroquinolin-4-yl) piperazine-1-yl) pyrrolidin-2-yl) methanone derivatives, CQPPM-9 both 
showed a decline in the total parasitaemia present over time (Figure 3.3A and 3.4A). The 
derivatives showed similar stage specific effects at the IC50 and IC90 concentrations, with 
differences observed in the parasite numbers being lower at the IC90 (Figure 3.3B and 3.4B). 
The only morphological differences observed between the parasites treated at the IC50 and 
IC90 concentrations for both derivatives was the smaller (pyknotic) appearance of the 
parasites when compared to the untreated control. 
44 
 
0 6 12 18 24 30 36
0
2
4
6
8
CQPA-26 IC50
CQPA-26 IC90
B
Time (hr)
T
o
t
a
l 
p
a
r
a
s
it
a
e
m
ia
 (
%
)
0
2
4
6
8
10
CQPA-26
Quinine
Drug-free control
A
6 12 18 24 3630
Time (hr)
T
o
t
a
l 
p
a
r
a
s
it
a
e
m
ia
 (
%
)
 a
t
 I
C
5
0
 
 
 
 
Figure 3.3: Changes in total parasitaemia between the most active CQPA-26 from the 7-
          chloroquinolin-4-yl piperazine-1-yl acetamide derivatives in comparison to the
          standard quinine and untreated (drug-free) control (A) with an indication of the
          difference between total parasitaemia at the IC50 and IC90 values of CQPA-26
          (B). 
 
Both derivatives progressed through the ring stage of the lifecycle of the parasite with no 
notable stage-specific morphological changes. Trophozoites developed within the same 
time-frame as the untreated control at 24 hrs into the lifecycle. However, derivative CQPPM-
9 showed a lag in progression from trophozoites to schizonts which was similar to the effects 
of quinine and CQPA-26 showed no schizont development. At the time when the untreated 
control showed complete progression into schizonts (100%), 97% of parasites treated with 
CQPA-26 and 85% treated with CQPPM-9 remained in the trophozoite stage, with only 15% 
of parasites treated with CQPPM-9 progressing into schizonts. The parasites treated with 
quinine also showed a lag in progression into schizonts, with 79% remaining in the 
trophozoite stage (Figure 3.5). 
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Figure 3.4: Changes in total parasitaemia between the most active derivative from 4-((7- 
        chloroquinolin-4-yl) piperazine-1-yl) pyrrolidin-2-yl) methanone derivatives 
        (CQPPM-9) in comparison to the standard quinine and untreated (drug-free)  
       control (A) with the difference IN total parasitaemia at the IC50 and IC90 values 
       of CQPPM-9 (B). 
 
Despite the lag in progression from trophozoite to schizont stage, derivative CQPPM-9 and 
quinine showed completion of the cycle and progression into the new cycle as evident in the 
the development of rings (10% and 12%, respectively) compared to the untreated control 
(73%). However, the average total parasitaemia was very low in comparison to the untreated 
control. Derivative CQPA-26, showed no completion of the cycle, with no progression into 
new rings (0%) (Figure 3.5 and 3.6). 
The parasites treated with the derivative CQPPM-9 were notably smaller in size (pyknotic) in 
comparison to the untreated control. Haemozoin formation was visible in the parasites 
treated with CQPA-26 and CQPPM-9, however the crystals were not as distinct and as 
compact as in the control. CQPA-26 parasites showed very light staining whereas CQPPM-9 
produced a very dark intense staining. Parasites treated with derivative CQPA-26 showed 
signs of vacuolisation with swelling of the digestive vacuole (Figure 3.5). 
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Figure 3.5: The effects of CQPA-26, CQPPM-9 and quinine (IC50 concentration) on parasite
        morphology and development over time. 
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Figure 3.6: Effects of each derivative (IC50) and standard quinine (IC50) on each stage (rings
        (A), trophozoites (B), schizonts (C) in the life cycle of the parasite over time (hr). 
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3.4 Solubility and permeability predictions 
The most active derivatives both complied with Lipinski’s rule of five having no violations. 
Derivative CQPA-26 and CQPPM-9 had molecular weights less than 500 g/mol, hydrogen 
bond donors less than five and hydrogen bond acceptors less than ten. The log P values of 
both derivatives tested adhered to Lipinski’s rule in the range between 0 to 5 (Table 3.3). 
These predictions prove these derivatives to be drug-like compared to quinine with good 
solubility. 
Table 3.3: Predicted solubility and permeability of the most active derivatives using Lipinski’s
       rule of five. 
 
 
3.5 Predicted ionisation and absorption as a function of pH 
The ionisation of the most active compounds were predicted at a pH similar to that of the red 
blood cell cytosol (pH 7.4) and at a pH similar to that of the digestive vacuole of the parasite 
(pH 5) (Table 3.4).  Quinine, being a diprotic weak base and in its unprotonated form, 
diffuses through the membranes of the parasitised erythrocyte and accumulates in the acidic 
digestive vacuole. Once inside the vacuole, it becomes protonated and as a consequence 
becomes trapped in the acidic compartment of the food vacuole (Figure 1.8). CQPA-26 
displays similar properties to quinine in being diprotic and since it is not ionised in the red 
blood, 100% diffuses into the food vacuole where it accumulates. In contrast, only 3% of 
CQPPM-9, traverses into the food vacuole, as the majority of it is ionised and trapped in the 
red blood cell (96.93%).  However, of the small percentage of CQPPM-9 found in the food 
vacuole, almost all of it (99.99%) is ionised and trapped to confer its effect (Table 3.4). 
 
 
Compound 
 
 
MW (g/mol) 
<500 
 
Hydrogen 
bonds 
donors <10 
 
Hydrogen 
bond 
acceptors 
<5 
 
Log P 
<5 
 
Rule of five 
violations 
CQPA-26 388.89 1 6 1.77 0 
CQPPM-9 487.01 0 7 2.68 0 
Quinine 324.42 1 4 3.44 0 
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Table 3.4: Predicted ionisation of the most active derivatives. 
Compound pKa % ionisation 
@ pH 7.4 
% ionisation @ 
pH 5 
% GIT 
Absorption 
CQPA-26 15.3, 8.41 0 100 100 
CQPPM-9 8.91 96.93 99.99 3.07 
Quinine 9.7, 5.072 0.5 54 99.5 
1pKa predicted using ACD/iLab version2 
2pKa values from Fegas et al. (2006) 
 
3.6 Larvicidal activity 
The twenty-seven 7-chloroquinolin-4-yl piperazine-1-yl acetamide derivatives and the nine 4-
((7-chloroquinolin-4-yl) piperazine-1-yl) pyrrolidin-2-yl) methanone derivatives displayed no 
larvicidal activity compared to DDT (100% dead) at 0.5 µM which was 10 times the LC50 
value for DDT (LC50: 0.05 ± 0.004 µM) (Figure 3.7). The first set of derivatives displayed 
mortality to the larvae up to 5% (range: 0-5%), while all of the second set of compounds 
displayed 0% mortality against the larvae. 
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Figure 3.7: LC50 value (0.05 ±.004 µM) determination of DDT against An. arabiensis larvae. 
 
The progression of larvae from one growth stage to the next in the larval life cycle was not 
halted in any of the larvae treated with the derivatives (Figure 1.3). All larvae treated with the 
derivatives were able to progress to the pupae stage. The treated larvae retained normal 
movement when prodded in the cervical region (Table 3.5). In comparison, the DDT treated 
larvae showed complete impairment of movement with no progression in growth due to 
death at 24 hours. 
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Table 3.5: The lack of larvicidal activity by the derivatives (0.5 µM) on Anopheles larvae 
       compared to untreated and DDT treated (0.5 µM) larvae.  
Treat-
ment 
Effect 
after 24 
hrs 
Morpho-
logical 
changes 
Pupae 
development 
An. arabiensis (KGB) larvae 
 
Drug-free 
control 
 
 
 
Alive 
 
Mobility: 
no 
change 
*Normal 
appearance. 
*Antennae (A) 
& mouth brush 
(B) prominent. 
*Lateral hair 
(C) on 
abdomen & 
tracheal gills 
(D) clearly 
visible. 
Pupae 
developed. 
 
Progressed to 
growth stages.  
 
DDT 
positive 
control 
 
 
Dead 
 
Mobility: 
retarded 
*Shrinkage of 
larvae. 
*Antennae (A) 
& mouth brush 
(B) shrivelled. 
*Lateral hair 
(C) on 
abdomen not 
visible. 
*Narrowing of 
abdomen (E). 
*Tracheal gills 
still visible (D). 
No pupae 
developed.  
 
Growth stages 
halted. 
 
 
CQPA-26 
 
Alive 
 
Mobility: 
No 
change 
*No size 
change. 
*All segments 
intact. 
*Antennae (A) 
& mouth brush 
(B) prominent. 
* Abdominal 
lateral hair (C)  
& tracheal gills 
(D) clearly 
visible. 
Pupae 
developed. 
 
Progressed to 
normal growth 
stages. 
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…Table 3.5 continued 
Treat-
ment 
Effect 
after 24 
hrs 
Morpho-
logical 
changes 
Pupae 
development 
An. arabiensis (KGB) larvae 
 
CQPPM-9 
Alive 
 
Mobility: 
no 
change 
*Size 
remained 
consistent. 
*All segments 
intact. 
*Antennae (A) 
& mouth brush 
(B) prominent. 
*Lateral hair 
(C) & tracheal 
gills (D) on 
abdomen 
intact. 
Pupae 
developed.   
 
Progressed to 
growth stages 
normally. 
 
 
 
3.7 Cytotoxicity 
3.7.1 Haemolysis 
The inhibitory effects appeared to be directed against the intra-erythrocytic parasite rather 
than affecting the membrane integrity of the red blood cell host, as no haemolysis was 
observed for the 7-chloroquinolin-4-yl piperazine-1-l acetamide derivatives (range:0.1-1.43% 
lysis) compared to quinine (0.1%) and the Triton-X100 positive control (100% lysis) when 
screened at 50 µM (Table 3.3). Similarly, the 4-((7-chloroquinolin-4-yl) piperazine-1-yl) 
pyrrolidin-2-yl) methanone derivatives caused no significant red blood cell lysis (range: 0.1-
1.74% lysis) (Table 3.4). 
3.7.2 Cell viability 
The 7-chloroquinolin-4-yl piperazine-1-yl acetamide derivatives showed a good safety profile 
with low toxicity to human embryonic kidney epithelial cells (% inhibition average: 1.93 - 
53.85%) (Table 3.3). However, the 4-((7-chloroquinolin-4-yl) piperazine-1-yl) pyrrolidin-2-yl) 
methanone derivatives inhibited the human embryonic kidney epithelial cells more than the 
7-chloroquinolin-4-yl piperazine-1-yl acetamide derivatives and proved to be more to toxic to 
the human kidney epithelial cells (IC50 range: 14.67- 81.24 µM) than quinine (IC50: 275.6 
±16.46 µM) (Figure 3.8). None of the derivatives were as toxic as the anticancer drug 
camptothecin (IC50: 0.11 µM) (positive control). 
.  
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Figure 3.8: The cell viability (IC50) of the 4-((7-chloroquinolin-4-yl) piperazine-1-yl) pyrrolidin-
         2-yl) methanone derivatives against the HEK-293 cells in comparison to quinine
        and the positive control camptothecin at 50 µM. 
 
3.7.3 Lipid peroxidation 
None of the derivatives (50 µM) inhibited lipid peroxidation (range: 0 - 3.06% inhibition) 
compared to Trolox (74.01% ± 0.14) in comparison to quinine (0.01% ± 1.04 inhibition). 
3.7.4 Brine shrimp lethality activity 
All the derivatives showed minimal lethality to brine shrimp (0 - 4.7%) at 0.5 µM compared to 
potassium dichromate (>60% mortality) at 50 µM. All nauplii treated with the derivatives 
showed no structural morphological changes when viewed under a microscope (Table 3.6). 
Their mobility was not decreased or altered in any way when compared to the healthy 
untreated nauplii. 
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Table 3.6: Table showing no effect of derivatives on Artemia franciscana nauplii after 24  
       hours compared to the potassium dichromate (positive control) and the 
       negative (blank) control. 
Treatment 
 
Effect 
(Dead/alive) 
Morphological 
changes 
Artemia fransiscana nauplii 
 
Drug-free 
control 
(negative 
control) 
Alive 
(0% mortality) 
 
Mobility: free, 
fast movement 
*No change in 
size. 
*Antennae (A) & 
swimming 
appendages (B) 
moved freely. 
*Colour remained 
consistent (C). 
 
 
Potassium 
dichromate 
(positive 
control) 
Dead 
(100% 
mortality) 
 
Mobility: None 
*Nauplii shrivelled 
(D). 
*Antennae (A) & 
swimming 
appendages (B) 
shrivelled. 
*Colour darkened 
& thickening of 
cervical region (C). 
 
 
 
CQPA-26 
Alive 
(0% mortality) 
 
Mobility: Free, 
fast movement 
*Size remained the 
same. 
*Swimming 
appendages (B) & 
antennae (A) 
moved normally. 
*Colour remained 
the same (C). 
 
 
 
CQPPM-37 
Alive 
(0% mortality) 
*Nauplii size 
remained 
unchanged. 
*Antennae (A) & 
swimming 
appendages (B) 
showed no 
changes 
*Colour remained 
the same (C). 
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CHAPTER 4: Discussion 
The growing resistance of P. falciparum against the current line of drug therapies has 
warranted the need for the development of novel compounds. The two sets of derivatives in 
this study were based on the concept that since the standard antimalarial drug, chloroquine 
has a novel mechanism of action to target the parasite and has a good safety profile in all 
age groups including pregnancy, its core chloroquinoline structure was maintained and 
additional side chains added to produce single agent compounds with a possible dual action. 
The 7-chloroquinolin-4-yl piperazine-1-yl acetamide and 7-chloroquinolin-4-yl piperazine-1-yl 
pyrrolidin-2-yl methanone derivatives in this study contained an aromatic nucleus similar to 
chloroquine (Figure 4.1) combined with other scaffolds such as acetamides or 
sulphonamides. The aim was to achieve the combined effects of each of the 
pharmacophores via a piperazine linker in a single compound in the move towards novel 
drug discovery. 
 
4.1 7-Chloroquinolin-4yl derivatives 
The 7-chloroquinolin-4-yl piperazine-1-yl acetamide derivatives were synthesised such that 
the aminochloroquinoline group remained the same with the addition of an acetamide group 
linked by a piperazine linker (Figure 4.1). A study by Kumawat et al., (2011) employed the 
same concept keeping aminochloroquinoline as the core structure with an attached propyl 
group linked to a thiazine group. These compounds showed moderate results as 
antimalarials against the chloroquine-sensitive P. falciparum RKL-2 strain with a percentage 
of dead parasites between 5.0-18.5% in comparison to chloroquine (50%). The second 
group of derivatives synthesised namely the ((7-chloroquinolin-4-yl) piperazine-1-yl) 
pyrrolidin-2-yl) methanone derivatives bearing an aminochloroquinoline core structure with 
the addition of piperazine and pyrrolidine rings with a sulphonamide group (Figure 4.1). 
Studies by Salahuddin et al., (2013) illustrated that structural modifications to a 
chloroquinoline pharmacophore has good antimalarial activity. This study evaluated the 
antimalarial effect of novel chloroquinoline based sulphonamide hybrids against the 
chloroquine-resistant (FCR-3) strain with good antimalarial activity (IC50 range: 1.16-8.54 
µM) in comparison to quinine (IC50: 0.17 µM) (Salahuddin et al., 2013). Structure-activity 
relationship studies illustrated that the 4-aminochloroquinoline nucleus is necessary for the 
groups antimalarial activity and accumulation in the parasite vacuole (Kumawat et al., 2011). 
These evidences encouraged the development of the derivatives in this study such that 
modifications of the side chains gave rise to drugs with desirable bioactivity. 
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Figure 4.1: Rationale in structural design of the 7-chloroquinolin-4-yl piperazine-1-yl 
       acetamide derivatives (B) and 7-chloroquinolin-4-yl piperazine-1-yl pyrrolidin-2-yl
       methanone derivatives (C) compared to the standard chloroquinoline (A). 
 
4.1.1 Overcoming chloroquine resistance 
Resistance to chloroquine is largely through alteration of the drugs accumulation mechanism 
in the digestive vacuole of the parasite. Mutations in the P. falciparum chloroquine resistance 
transporter (pfCRT), a protein found in the parasite digestive vacuole, aids efflux of the 
positively charged chloroquine from the digestive vacuole. This leads to decreased 
accumulation of chloroquine in the parasite to levels which are safe for the parasite (Boudhar 
et al., 2016). With chloroquine not being used routinely, the drug pressure has been 
removed resulting in the loss or down-regulation of the resistance gene, making chloroquine 
and its mechanism of action viable again (Boudhar et al., 2016). This explains the rationale 
in keeping the chloroquinoline core structure in the design of the derivatives used in this 
study with the addition of acetamide or sulphonamide and pyrrolidine side chains to increase 
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the target sites against the parasite, while maintaining the efficacious core structure with 
known antimalarial activity. 
 
4.1.2 7-Chloroquinolin-4-yl piperazine-1-yl acetamide derivatives 
The chloroquinoline class has been identified as drugs with potent antimalarial activity with 
minimum inhibitory concentrations in the range of 0.05 to 0.11 µM (Gupta et al., 2008). The 
7-chloroquinolin-4-yl piperazine-1-yl acetamide derivatives in this study inhibited the NF54 
strain of the P. falciparum at varying degrees with minimum 50% inhibitory concentrations 
between 1.29 to 53.98 µM (Table 3.3).  The 27 derivatives did not alter the host red blood 
cell membrane integrity indicating that the activity was directed towards the intra-erythrocytic 
parasite (0.1-1.74% lysis) (Table 3.4). This illustrates a favourable property for the use of 
these derivatives as antimalarials. Considering the pathology of malaria which includes red 
blood cell haemolysis during parasite lifecycle (Figure 1.4), the antimalarial drug should not 
further compromise the patients uninfected red blood cells (Table 3.3). Derivatives CQPA-
26,25,19 showed five times higher antimalarial activity than CQPA-21 (Table 2.1; Figure 
4.2). This could be due to the introduction of the piperazine group in CQPA-21. The addition 
of a fluorine group in the ortho position of the aromatic amine decreased the antimalarial 
activity by three fold to produce the least active derivative CQPA-6 (IC50: 53.98 µM) (Table 
2.1). However, positioning the fluorine group in the para position in the aromatic amine 
increased the antimalarial activity 3 fold (CQPA-7 IC50: 18.75 µM)). This could be due to the 
effect of the ortho substituents which decrease the basic properties of the compound and 
thus decreasing its antimalarial effect. Studies by Sparatore et al., (2005), showed similar 
findings where substituents decreasing basicity caused decreased activity against the D-10 
and W-2 P. falciparum.  Contrastingly, moving of the position of a methyl group from the 
para position as in derivative CQPA-8 to the meta position in CQPA-10, only contributed to a 
slight increase in antimalarial activity (Figure 4.2). This is consistent with the findings of 
chloroquinoline-pyrimidine hybrids with a similar structure to the derivatives in this study 
(Kumar et al., 2014).  The addition of bulky groups did not improve antimalarial activity. A 
similar trend was observed in a study by Inam et al., (2015), where the reduction in both 
antimalarial (3D7-strain) and antiamoebic activity in the chloroquinoline-acetamide hybrids 
was attributed to the imposed steric hindrance of the bulky groups. The two most active 7-
chloroquinolin-4-yl piperazine-1-yl acetamide derivatives, CQPA-26 and CQPA-25, with IC50 
of 1.29 µM and 1.72 µM, respectively against the Plasmodium falciparum parasite showed 
no toxic effects against the host red blood cell and showed favourable results against normal 
cell lines with a percentage cell inhibition of 54.88% and 34.93%, respectively (Table 3.3). 
The activity of the cyclopropyl derivative, CQPA-26 could be due to the closing of the 
triangular side chain of the isopropyl derivative CQPA-24 (Figure 4.2). Furthermore, the 
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increased activity of derivative CQPA-26 could be correlated to the addition of the strong 
electron donating group (-OH) which would increase its basic properties and increase its 
activity against the parasite, particularly its accumulation in the parasite digestive vacuole. In 
studies by Sparatore et al., (2005), a decreased activity was seen when electron withdrawing 
groups were added to the side chain reducing the basic properties of the drug.  In a study by 
Boudhar et al., (2016), a similar approach as in this study was undertaken where hybrid 
compounds were developed in which the 4-aminochloroquinoline scaffold was maintained 
and linked to other scaffolds with a different mechanism of action, in an attempt to 
resensitise chloroquine-resistant parasites. The hybrid compounds in this latter study all 
showed IC50 values below 500nM against the Hb3 and 3D7 parasite strains (Boudhar et al., 
2016). This study highlighted the ability of new hybrids in resensitising chloroquine-resistant 
parasites. 
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Figure 4.2: Antimalarial activity and cytotoxicity of the key 7-chloroquinolin-4-yl   
        piperazine-1-yl acetamide derivatives. 
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4.1.3  7-Chloroquinolin-4yl piperazine-1 yl pyrrolidine-2yl methanone derivatives 
The nine 7-chloroquinolin-4-yl piperazine-1-yl pyrrolidin-2-yl methanone derivatives showed 
antimalarial activities with all IC50 values below 20 µM (IC50 range: 1.42-19.62 µM) (Table 
3.4). The inhibitory effects appear to be directed against the intra-erythrocytic parasite rather 
than the membrane of the red blood cell host, as no haemolysis was observed for all nine 
compounds (<1% lysis) compared to chloroquine (<0.1%) (Table 3.4). A similar trend was 
observed in a study by Salahuddin et al., (2013), in which a new series of 4-
aminocloroquinoline based sulphonamides showed no significant lysis of the human red 
blood cells. Derivative CQPPM-9 displayed the best safety profile (safety index: 57.14) and 
proved to be the most potent in inhibiting P. falciparum (NF54) from the nine derivatives. The 
methyl substitution of derivative CQPPM-9 increased the antimalarial activity compared to 
the tert-butyl substitution of derivative CQPPM-4 (4-fold) (Figure 4.3). The presence of a 
chlorine atom has been shown to increase the antimalarial potency of a compound, but this 
trend was not echoed with the 7-chloroquinolin-4-yl piperazine-1-yl pyrrolidin-2-yl methanone 
derivatives (Inam et al., 2014). 
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Figure 4.3: Antimalarial activity and cytotoxicity of the key 7-chloroquinolin-4-yl piperazine-1-
      yl pyrrolidin-2-yl methanone derivatives. 
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4.2 Beta-haematin inhibition 
The presence of an aromatic nucleus has shown positive results in malaria 
chemotherapeutics for its haematin binding affinity (Figure 4.4). The presence of the 7-
chloroquinoline moiety in antimalarial compounds has been shown to be a necessary factor 
in binding to haematin in the parasites’ acidic food vacuole, thereby inhibiting haemozoin 
formation (Gupta et al., 2008). The presence of the 7-chloroquinoline moiety in both the 7-
chloroquinolin-4-yl piperazine-1-yl acetamide and 7-chloroquinolin-4-yl piperazine-1-yl 
pyrrolidin-2-yl methanone derivatives could be the possible mechanism of action of these 
derivatives (Figure 4.1). This is backed by a study by Inam et al, (2015) which showed that 
the aminochloroquinoline moiety of the chloroqunoline-acetamide hybrids inhibited β-
haematin formation. The aromatic quinoline nucleus present in these derivatives is 
necessary to intercalate onto the surface of the FPIX to form a drug-haem complex (Leed et 
al., 2002).  The drug-haem complex is incorporated into the growing dimer chains preventing 
further sequestration of toxic haem and disrupting membrane function (O’Neill et al., 2012) 
(Figure 4.4). 
 
 
Figure 4.4: Proposed mechanism of action of quinoline-based drugs showing degradation of
        haemoglobin and detoxification mechanisms of the parasite (O’Neill et al., 2012). 
 
The quinoline ring present in both the 7-chloroquinolin-4-yl piperazine-1-yl acetamide and 7-
chloroquinolin-4-yl piperazine-1-yl pyrrolidin-2-yl methanone derivatives may intercalate with 
the porphyrin groups on the surface of the haematin crystal (Figure 4.5 (A)). The quinoline 
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nitrogen group can form a hydrogen bond with the vinyl group of the porphyrin ring (Figure 
4.5 (B)). 
 
Figure 4.5: Theoretical binding sites of derivatives aminochloroquinoline core with the 
        haemozoin crystal (Buller et al., 2002; Weissbuch & Leiserowitz, 2008). 
 
Furthermore, the chlorine substituent in the quinoline ring has been shown to contribute to 
increased antimalarial activity and inhibition of haemozoin formation (Egan et al., 2000) 
(Figure 5.4). The 7-chloroquinoline moiety in both the 7-chloroquinolin-4-yl piperazine-1-yl 
acetamide and 7-chloroquinolin-4-yl piperazine-1-yl pyrrolidin-2-yl methanone derivatives 
possess the quinoline group in its core structure, as well as the chlorine substituent in the 
quinoline ring which is consistent with the studies by Egan et al, (2000) in conferring β-
haematin inhibitory properties as a mechanism of action. The 7-chloro group of the 
derivatives can interact with a methyl group of a neighbouring porphyrin moiety of haematin 
(Figure 4.5 (C)). 
 
4.3 Drug accumulation in parasite digestive vacuole 
Quinolines target the food vacuole of the intraerythrocytic malaria parasite. The weak basic 
properties of these drugs allow them to accumulate in the acidic vacuole of the P. falciparum 
parasite via transmembrane pH gradients (Yayon et al.,1985) (Figure 4.7). Studies by Yayon 
et al, (1985) suggest that the antimalarial activity of chloroquine is exerted by alkalanisation 
of accumulated drug interfering with vital cellular functions of the food vacuole. The 7-
chloroquinolin-4-yl piperazine-1-yl acetamide and 7-chloroquinolin-4-yl piperazine-1-yl 
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pyrrolidin-2-yl methanone derivatives contain a protonatable quinoline nitrogen (Figure 4.6: 
nitrogen in blue) that would increase the accumulation of the derivatives in the parasite 
vacuole. The increased antimalarial activity of the 7-chloroquinolin-4-yl piperazine-1-yl 
acetamide derivative CQPA-26, could be due to increased diffusion and accumulation 
(100%) into the parasite food vacuole (Table 3.4). This derivative shows similar properties to 
chloroquine in conferring ion trapping properties due to its diprotic weak base nature (Figure 
4.6). This is further supported by its ionisation capabilities and good solubility from drug-
likeness predictions using Lipinski’s rule of five (Table: 3.3, 3.4). The weak basic nature of 
the derivatives could contribute to its mechanism of action in that by increasing the pH of the 
parasite digestive food vacuole, it would affect the functionality of the acid proteases of the 
parasite, thereby preventing haemoglobin digestion and resulting in parasite death (Figure 
4.7; 4.8) (Homewood et al., 1972). 
 
 
Figure 4.6: Proposed structure-activity relationships according to studies by Egan et al.,  
       (2000). 
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Figure 4.7: Diffusion and accumulation of chloroquine into the parasite digestive food 
        vacuole due to the pH gradient (O’Neill et al., 2012).  
 
4.4 Protein synthesis inhibition 
Plasmodium proteases are involved in pathways that are essential for the parasite survival. 
This makes them a suitable target for drug development due to their enzymatic mechanisms 
and active site structures (Deu, 2017). Apart from the proposed mechanism of action of 
quinolines in inhibiting haemozoin formation, it has been proposed that quinolines inhibit 
parasite protein synthesis (Rosenthal et al., 1996). This occurs in the parasitic digestive food 
vacuole following degradation of haemoglobin into haem and globin (Figure 1.8) and the 
latter is further degraded to amino acids that are used as building blocks for parasitic protein 
in a process involving haemoglobinases (Dominguez et al., 1997). Given that malarial 
parasites have limited capacity for de novo amino acid biosynthesis, the majority of amino 
acids required for the parasite’s own protein biosynthesis and energy metabolism are 
supplied by haemoglobin degradation products. Malaria parasites express a number of 
proteases in the food vacuole for the degradation of haemoglobin imported from the host’s 
red blood cell (Dominguez et al., 1997). The haemoglobin degradation process follows a 
well-ordered pathway as outlined in Figure 4.8. 
Aspartic protease inhibitors and the cysteine protease inhibitors are two classes of these 
enzyme inhibitors with antimalarial effects. It can be proposed that the most active 7-
chloroquinolin-4-yl piperazine-1-yl acetamide derivative, CQPA-26 possessed inhibitory 
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properties similar to a cysteine protease inhibitor. Inhibition of falcipain, a cysteine protease, 
was shown to halt parasite development and an abnormal appearance of the food vacuole 
with accumulated undergraded haemoglobin (Dominguez et al., 1997). Derivative CQPA-26 
caused similar morphological changes as those seen with falcipain inhibitors where the 
parasitic food vacuole appeared swollen, with parasite development halted in the trophozoite 
stage and no progression to the schizont stage. Parasites treated with derivative CQPA-26 
did not complete the cycle to form new ring-stage parasites (Figure 3.1, >36hrs). Studies by 
Dominguez et al., (1997), show that phenothiazines inhibited falcipain with morphological 
abnormalities showing vacuolization of the parasite cytoplasm and limited development 
beyond the trophozoite stage. This inhibition could be due to the binding of the 7-
chloroquinolin-4-yl piperazine-1-yl acetamide derivative to the falcipain active site in a 
manner analogous to that predicted for chalcones (Mishra at al., 2008). Like the chalcones, 
derivative CQPA-26 shows structural stability in the acidic vacuole due to its weak base 
properties (Section 3.5) which allows for binding to the falcipain active site (Mishra at al., 
2008). Furthermore, the spacing of the nitrogen atoms in the derivatives is proposed to be 
necessary and more effective in binding to the enzyme active site (Mishra at al., 2008). 
 
Figure 4.8: Protein synthesis pathways in the Plasmodium parasite indicating digestion of 
host haemoglobin in the parasites digestive vacuole (i). Endopeptidases such as aspartic 
proteases (plasmepsins) and cysteine proteases (falcipains) (ii) initiate catabolism (iii), 
reducing peptides to dipeptides (iv). These smaller peptide fragments are transported to the 
parasite cytosol (v) where they are further broken down to amino acids (vi). (Skinner-Adams 
et al., 2010). 
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Mahesh at al. (2014) outlines the necessary pharmacophore essential for falcipain inhibitors. 
The study outlines that an aromatic moiety is necessary with hydrogen bond donors and 
acceptors of between 0 to 2 and 2 to 6, respectively; as well as a basic nature of the 
molecule confers falcipain inhibitory activity. Derivative CQPA-26 contains all of these 
necessary structural features, with hydrogen bond donors (1) and acceptors (6) within the 
range (Table 3.3) and the amino moiety conferring the basic nature. Mahesh et al. (2014), 
illustrated in a group of compounds which contained an acetamide moiety like CQPA-26 
showed good antimalarial activity against Plasmodium falcipain enzyme (>60%) at low 
concentrations (10 µM) and attributed its activity to the acetamide moiety. Like the 
chalcones, the free nitrogen in the 7-chloroquinolin-4-yl piperazine-1-yl acetamide 
derivatives allow for protonation or hydrogen bonding with the active histidine site of the 
falcipain enzyme as proposed by Mishra et al. (2008) (Figure 4.8). It can be deduced that the 
activity of derivative CQPA-26 against could be driven by the covalent interaction with 
falcipain.  
 
Figure 4.9: Proposed mechanism of binding of chalcone to histidine site of falcipain enzyme
        Mishra et al., (2008). 
 
Unlike parasites treated with CQPA-26, parasites treated with 7-chloroquinolin-4-yl 
piperazine-1-yl pyrrolidin-2-yl methanone, CQPPM-9 derivative, did progress eventually to 
the schizont stage (after 36 hrs). However, progression was much slower than the control 
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and quinine (30-32 hours) with a reduction in haemozoin production (Figure 3.5). The 
observation of pyknotic trophozoites detailed in this study with derivative CQPPM-9, with no 
effect on early ring stages and eventual progression to the schizont stage could imply that 
the derivative exerts its toxic effects in the late stages of the erythrocytic lifecycle where DNA 
synthesis peaks. This trend is in line with the trends seen with all antifolates and supports 
the proposed mechanism as a folate inhibitor due to the presence of the sulphonamide 
moiety (Ekoue-kovi et al., 2009) (Figure 4.11). It prevented the emergence of a new life cycle 
with no new rings being formed compared to the control, thus arresting development in the 
schizont stage (Figure 3.5). The CQPA-26 derivative did not progress to the schizont stage 
and predominantly remained in the trophozoite stage, with swelling of the vacuole and 
diminished haemozoin formation which supports the earlier proposed mechanism in 
inhibiting haemozoin formation (Figure 3.5). 
 
4.5 Inhibition of parasite folate pathways 
The presence of the amide in the 7-chloroquinolin-4-yl piperazine-1-yl acetamide derivatives 
is characteristic to the structure of proguanil and could exhibit similar DHFR inhibitory effects 
in the parasites folate pathway as an additional mechanism of action (figure 4.8) (Rastelli et 
al., 2003; Madapa et al., 2009). This results in inhibition of parasite DNA synthesis (Figure 
1.10). A study by Mahesh et al. (2014), in which acetamide derivatives similar to the 
acetamide side chains in the 7-chloroquinolin-4-yl piperazine-1-yl acetamide derivatives 
showed good antimalarial activity against Plasmodium at low concentrations (10 µM) due to 
its acetamide moiety (Figure 4.10). 
 
Figure 4.10: Structural similarities between 7-chloroquinolin-4-yl piperazine-1-yl acetamide
          derivatives (a), Proguanil (b), and 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)-
         N-phenylacetamide derivatives (c) (Mahesh et al., 2014). 
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 It is proposed that the sulphonamide side chain present in the 7-chloroquinolin-4-yl 
piperazine-1-yl pyrrolidin-2-yl methanone derivatives (Figure 4.11a) also play a role in 
inhibiting the folate pathway in the parasite, but does so by inhibiting the enzyme DHPS 
(Hogh et al., 2000). Studies show that the introduction of a sulphonamide side chain to 
chloroquine analogues displayed higher antimalarial activity and a low resistance index 
(Ekoue-kovi et al.,2009). From studies by Jatakiya et al.,(2014), it was deduced that the 
sulphonamide substitution was necessary for better antimalarial activity against Plasmodium 
in a group of novel N-substituted piperazine derivatives against the 3D7 strain of P. 
falciparum. The derivatives in this study displayed a higher antimalarial activity with a 
sulphonamide substituted group at the para position in comparison to a methyl, methoxy or 
chloro substitution in the same position (Jatakiya et al., 2014). The 7-chloro-4-aminoquinolyl 
derived sulphonamides (Figure 4.11b), showed antimalarial activity in the range nanomolar 
range upon introduction of the sulphonamide moiety against the HB3 (chloroquine sensitive) 
(IC50 range: 10-272 nM) and the Dd2 (chloroquine resistant) (IC50 range: 23-260 nM) strains 
of P. falciparum (Ekoue-kovi et al., 2009). This could be due to the dual mechanism of action 
of the chloroquinoline in inhibiting haemozoin formation and the sulphonamide moiety in 
interrupting the folate pathway (Figure 1.10). A novel hybrid set of compounds were studied 
by Boudhar et al., (2016), in which a similar approach was undertaken as in this study to 
create a novel hybrid combining a haem-binding aminochloroquinoline with a 
dihydropteroate synthase-inhibiting sulphonamide group. These hybrids displayed promising 
antimalarial activity against the chloroquine-sensitive 3D7 strain and the chloroquine-
resistant K1 strain with IC50 values below 500 nM for both strains (Boudhar et al., 2016). 
 
Figure 4.11: Structural similarities of sulphonamide moiety in the 7-chloroquinolin-4-yl 
        piperazine-1-yl pyrrolidin-2-yl methanone derivatives (a) compared to the 7- 
        chloro-4-aminoquinolyl derived sulphonamides (b) (Ekoue-kovi et al., 2009). 
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4.6 Combination therapy 
The current most effective antimalarial treatment available is an artemisinin-based 
combination therapy (ACT). Unfortunately, in places such as Thailand and Cambodia, ACT 
has shown prolonged clearance rates (Boudhar et al., 2016). The threat of developing 
resistance to antimalarials has led to the search of novel combination therapies to prevent 
drug resistance. The structure of the 7-chloroquinolin-4-yl piperazine-1-yl acetamide 
derivatives owing to different mechanisms of target in the parasite could be the reason for 
the synergistic combination effect with quinine. In the treatment of microbial infections, 
combination therapy is preferred to monotherapy to delay the emergence of resistant 
parasites (Bell, 2005). The most active derivative from the 7-chloroquinolin-4-yl piperazine-1-
yl acetamide derivatives showed a synergistic effect in combination with quinine (Figure 
3.2A). This proves to be favourable as in addition to reducing the emergence of resistance, 
combination therapy allows for the reduction in doses needed of the individual agents 
thereby minimizing adverse effects and costing of the treatment regimen (Bell, 2005). With 
derivative CQPA-26 containing the basic core structure as quinolines, the addition of side 
chains which introduce different target pathways in the parasite, allows for a synergistic 
effect without competition for binding sites nor inhibition of one drug to the other at the same 
binding sites within the parasite. Unlike chloroquine and quinine with the same target 
pathways contributing to an antagonistic combination effect (Bell, 2005). 
Derivative CQPPM-9 showed an overall additive effect when combined with quinine (Figure 
3.2B). The additive combination effect could be due to the quinine acting on the late 
trophozoite stage of the parasite and CQPPM-9 acting from the early trophozoite stages of 
the parasite lifecycle. Acting on different stages, allows for an additive effect without 
enhancing nor inhibiting the effects of the individual drugs. The individual FIC at the highest 
derivative concentration, showed an antagonistic effect in comparison to the overall additive 
effect. The high concentration of derivative binding to haem may result in reduced 
concentrations of free haem for quinine to bind to and therefore bringing about an 
antagonistic effect similar to that seen with combinations like mefloquine and chloroquine 
(Bell, 2005). 
 
4.7 Toxicity 
The search for novel compounds in the treatment of malaria is complicated as the 
antimalarials need to target the parasite within the host red blood cell without affecting the 
integrity of the host cells. All of the derivatives did not affect the red blood cell membrane 
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stability, causing red blood cell membrane lysis of <2% compared to quinine (0.1%) at a 
concentration of 50 µM (Section 3.7.1). This was a favourable effect, demonstrating that the 
antimalarial activity was directed towards the intra-erythrocytic parasite. The favourable 
safety profile was further displayed by the 7-chloroquinolin-4-yl piperazine-1-yl acetamide 
derivatives with little effect on cell viability (% inhibition 1.93-53.85%) (Table 3.1), requiring 
high concentrations, hence a high therapeutic window (Boudhar et al., 2016). The 7-
chloroquinolin-4-yl piperazine-1-yl pyrrolidin-2-yl methanone derivatives, however proved to 
be more toxic to human kidney epithelial cells (IC50 range: 14.67 - 581.24 µM) than quinine 
(IC50: 275.6 µM). The most active antimalarials from both groups, CQPA-26 and CQPPM-9, 
displayed the least effects on cell viability (IC50: 54.88 and 81.24 µM) (Table 3.1 and 3.2), 
increasing the therapeutic window of these derivatives. The low toxicities associated with the 
derivatives was further echoed with no lethality towards the brine shrimp (0 - 4.75 mortality) 
compared to potassium dichromate (>60%) (Table 3.6). The quinoline derivatives have been 
proven to exhibit diverse biological activities including anticancer properties (Ghorab et al., 
2016). A recent study evaluated the anticancer properties of quinoline as well as 
sulphonamide hybrids, similar in structure to those in this study and showed good cytotoxic 
activity against lung (IC50 range: 44.34 - 76.73 µg/ml), colorectal (IC50 range: 28.82 - 104.78 
µg/ml), and breast cancer (IC50 range: 26.54 - 115.11 µg/ml) lines compared to the reference 
drug DCF (124.87, 114.12, 113.94 µg/ml), as a PI3K inhibitor, which is a vital signal 
transductory enzyme (Figure 4.12) (Ghorab et al., 2016). Such studies provide a basis for 
further evaluation of these derivatives in the search for compounds with multiple activities 
against malaria, vectors and cancers. 
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Figure 4.12: Binding sites of novel chloroqunoline sulphonamide hybrid in cancer cells with
           structural similarities (chloroquinoline and sulphonamide scaffolds) as the 7-
           chloroquinolin-4-yl piperazine derivatives in this study (Ghorab et al., 2016). 
 4.8 Vector effects 
The pharmacological properties of both the 7-chloroquinolin-4-yl piperazine-1-yl acetamide 
and 7-chloroquinolin-4-yl piperazine-1-yl pyrrolidin-2-yl methanone derivatives were directed 
towards the intra-erythrocytic stage of the malaria parasite life cycle rather than the vector 
stages, displaying no larvicidal activity compared to DDT (Section 3.6) 
Larvicidal management to reduce adult mosquito population involves effective control of 
mosquito larvae with the least impact on human health and the environment. Studies show a   
growing resistance to insecticides such as DDT and the environmental concerns associated 
with insecticides used in larval control (Mohammed et al., 2015).  Most studies focus on 
larvicides of natural and botanical origin due to their limited adverse effects on the 
environment and beneficial organisms. A study by Begum et al., (2011) looked at the 
larvicidal properties of novel chalcones. Looking at the structure-activity relationships, 
chalcones with an electron donating group on ring A or B showed high toxicity to the larvae 
of the common house Culex quinquefasciatus (Begum et al., 2011) (Figure 4.13 (a)). Based 
on the findings by Begum et al., (2011), the presence of the electron withdrawing group 
present in the 7-chloroquinolin-4-yl piperazine-1-yl acetamide and 7-chloroquinolin-4-yl 
piperazine-1-yl pyrrolidin-2-yl methanone derivatives in this study, could be the reason for 
their ineffective larvicidal properties (Figure 4.13 (b & c)). In another study in which acridone 
derivatives were screened for larvicidal activity, pyrazolo fused acridine isomers showed 
promising larvicidal activity against the yellow fever virus vector Aedes aegypti (Roopan et 
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al., 2017). These acridine isomers contain the same heterocycle nucleus as the derivatives 
in this study which is imperative for antimalarial activity, but differ in the presence of 
additional heterocycles (Figure 4.13 (d)). This provides a basis for adapting the current 
derivatives by adding an additional heterocycle to improve larvicidal activity, while 
maintaining its antimalarial core structure. 
Looking at the structural differences between the 7-chloroquinolin-4-yl piperazine-1-yl 
acetamide and 7-chloroquinolin-4-yl piperazine-1-yl pyrrolidin-2-yl methanone derivatives in 
comparison to current insecticides used, a common differential feature is the lack of the 
chloroquinoline aromatic nucleus in current insecticides which is an important feature in 
conveying antimalarial properties and would suggest that mimicking these structures would 
lead to compounds with no antimalarial properties and only larvicidal properties (Table 4.1). 
Furthermore, adapting the same chemical structure as current insecticides would not be 
ideal as it would not resolve the rising resistance to these insecticides and the toxicities 
associated with them. It is possible that in evaluating the structural differences of the 
derivatives in this study to current insecticides, removal of the fused rings in the 7-
chloroquinolin-4-yl piperazine-1-yl acetamide and 7-chloroquinolin-4-yl piperazine-1-yl 
pyrrolidin-2-yl methanone derivatives would produce larvicidal activity. However, whether the 
antimalarial activities would still be present will need to be re-evaluated. 
 
 
Figure 4.13: Structural differences and similarities between novel chalcone (a) and acridine
           isomers (b) with larvicidal properties in comparison to the 7-chloroquinolin-4-yl
          piperazine-1-yl acetamide (c) and 7-chloroquinolin-4-yl piperazine-1-yl 
          pyrrolidin-2-yl methanone (d) derivatives showing no larvicidal properties. 
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Table 4.1: Chemical structures of larvicides approved by WHO. 
Larvicide Chemical structure 
DDT 
 
Temephos  
Methoprene 
 
Pyripoxifen 
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CHAPTER 5:  Conclusion, limitations & recommendations 
 
Both classes of derivatives provided an ideal scaffold with numerous proposed mechanisms 
of actions that makes it worthwhile to further investigate these derivatives. The 
chloroquinoline core structure similar to that in the standard antimalarial chloroquine confers 
good antimalarial activity and beta-haematin inhibition that has been studied extensively 
(Gupta et al., 2008). Drawing from the existing widespread resistance to the chloroquinoline 
class of drugs, the novel derivatives in this study built on the basic core structure by adding 
side chains with different mechanisms of action to increase activity and reduce the possible 
potentiation in resistance. The one set of derivatives contained an acetamide group linked to 
a chloroquinoline group by a piperazine linker (Figure 5.1A), whilst the second set contained 
a sulphonamide moiety linked to a chloroquinoline core by a piperazine and pyrrolidine linker 
(Figure 5.1B). The acetamide and sulphonamide groups are known to inhibit folate synthesis 
thereby inhibiting parasite DNA synthesis (Figure 5.1) (Rastelli et al., 2003; Hogh et al., 
2000). Derivatives CQPA-26, CQPA-25 and CQPPM-9 in particular are worth further study 
due to their good antimalarial activity and low toxicity against the host red blood cell and 
human epithelial (HEK-293) line (Table 3.1 and 3.2). These derivatives were less active than 
the standard antimalarial, quinine, but further structural modifications may increase the 
antimalarial activities, while maintaining their safety profiles. The addition of a quinolizidine 
ring to a chloroquinoline core structure of both sets of derivatives may increase the 
antimalarial activity, as it did against the W-2 chloroquine-resistant strain of P. falciparum 
with antimalarial activity ten times that of chloroquine (Sparatore et al., 2005). Furthermore, 
studies by Salahuddin et al.,(2013), showed that the addition of an acetylaniline side chain to 
an aminochloroquinoline-based sulphonamide increased antimalarial activity of the structure 
to yield the most active compound from the group with an IC50 value of 2 µM against the 
chloroquine-resistant FCR-3 strain of P. falciparum.  
Looking at the structural differences between the 7-chloroquinolin-4-yl piperazine-1-yl 
acetamide and 7-chloroquinolin-4-yl piperazine-1-yl pyrrolidin-2-yl methanone derivatives in 
comparison to current insecticides, a common differential feature is the lack of the 
chloroquinoline aromatic nucleus in current insecticides. This is an important feature in 
conveying antimalarial properties and would suggest that mimicking these structures would 
lead to compounds with no antimalarial properties and only larvicidal properties (Table 4.1). 
Furthermore, adapting the same chemical structure as current insecticides would not be 
ideal as it would not resolve the developing resistance to these insecticides and the toxicities 
associated with them. Perhaps, in evaluating the structural differences of the derivatives in 
this study to current insecticides, removal of the fused rings in the 7-chloroquinolin-4-yl 
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piperazine-1-yl acetamide and 7-chloroquinolin-4-yl piperazine-1-yl pyrrolidin-2-yl 
methanone derivatives would produce larvicidal activity. However, whether the antimalarial 
activities would still be present will need to be re-evaluated. 
 
 
 
Figure 5.1: Proposed structure-related mechanisms of action of 7-chloroquinolin-4-yl 
        piperazine-1-yl acetamide (A) and 7-chloroquinolin-4-yl piperazine-1-yl 
        pyrrolidin-2-yl methanone (B) derivatives in this study. 
 
The most active derivatives CQPA-26 and CQPPM-9 displayed drug-like properties based 
on the Lipinski’s rule of five (Ro5), with the predicted % ionisation at pH 5 indicating that they 
would accumulate in the parasite digestive vacuole like quinine and chloroquine (Table 3.3, 
3.4). This is indicative of the acid-base properties facilitating its mode of action. Derivative 
CQPA-26 displayed a synergistic combinatory effect with quinine (ƩFIC: 0.29), whilst 
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CQPPM-9 displayed an additive effect in combination with quinine (ƩFIC: 1.31). This showed 
potential for both of these derivatives to be used in combination with quinine without altering 
the antimalarial activity negatively. 
The negligible effect of the derivatives on the mosquito vector itself is suggestive that these 
compounds should not be further investigated for any larvicidal activity but rather focus on 
their intra-erythrocytic antimalarial activity. Furthermore, testing the activity of the derivatives 
against the sexual stages of the parasite life cycle may be worthwhile to not only treat the 
human host but to block transmission. However, a favourable non-toxic effect was shown by 
all derivatives against brine shrimp (0-4.7% lethality), which further highlights the favourable 
safety profile of the derivatives. With the multiple mechanisms of actions, further 
experimentation on the mechanisms of action in inhibiting beta-haematin formation, folate 
synthesis and the direct effect on the Plasmodium protease enzymes would be feasible. 
Based on this study, the limited supply of the derivatives with no access to additional 
compounding of the derivatives was a major limitation preventing further experimentation on 
the mechanisms of action especially the β-haematin inhibitory effects. The morphological 
effects of derivative CQPA-26 and CQPPM-9 in causing a lag in progression beyond the 
trophozoite stage of the parasite with no progression to a new lifecycle (Figure 3.5), 
indicates that other modes of action needs to be explored. The structure-activity information 
from this study can be used for further development and synthesis of improved second 
generation derivatives. In addition to antimalarial properties, further studies with regards to 
multiple biological activities such as the anticancer and antiprotozoal properties of the 
derivatives would be promising as studies of compounds with a similar structural scaffold as 
the derivatives in this study showed positive results (Inam et al., 2015).  
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